Top

David R. Piwnica-Worms, M.D., Ph.D.

Department of Cancer Systems Imaging, Division of Diagnostic Imaging

About Dr. David R. Piwnica-Worms

The tools of molecular imaging can provide spatially- and temporally-resolved information on biological structures and functions. Because investigators have increasingly recognized the importance of context in the study of gene expression and protein function as well as understanding regulatory mechanisms within cellular micro-environments, many have turned to non-invasive imaging technologies to advance research on human health and disease. These non-invasive imaging strategies can interrogate protein processing, protein-protein interactions, gene expression and flux through metabolic pathways in real-time in cells and live animals, and are increasingly useful in understanding signal transduction and pathobiology of human diseases, including cancer, to facilitate development of effective therapies. His group has used these approaches to investigate mechanisms of regulation of IkB/NFkB signaling, b-catenin processing, multidrug resistance, EGFR signaling, and innate immunity. They have developed high fidelity molecular-specific pharmacodynamic reporters of several anti-cancer drugs useful in whole animal models. They have created a widely-used luciferase protein fragment complementation platform, dual-color protein interaction switches, and fusion reporters for bioluminescent analysis of protein processing in living animals, each with broad applications in biotechnology and biomedicine. By making these constructs and methods freely available, the team helped catalyze the application of genetically-encoded molecular imaging approaches to diverse medical and basic biological questions in a variety of fields. On other fronts, Piwnica-Worm’s group has moved several of their scientific discoveries from bench to bedside, facilitating the goals of precision medicine by translating novel PET tracers and cell-penetrating activatable peptides toward clinical imaging applications.

Primary Appointment

Professor, Department of Bioengineering, Division of Diagnostic Imaging, Rice University, Houston, TX

Endowed Distinguished Chair Gerald Dewey Dodd, Jr., Endowed Distinguished Chair in Diagnostic Imaging, Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Department Chair, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor (Joint appointment), Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX

Executive Director, Quantitative Imaging Analysis Core (QIAC), Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Bioengineering, Rice University, Houston, TX

Gerald Dewey Dodd, Jr., Endowed Distinguished Chair in Diagnostic Imaging, Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX

Graduate Faculty, Department of Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX

Research Interests

Molecular imaging of signal transduction pathways and protein-protein interactions in vivo; dynamic analysis of B7-H3 immune checkpoint signaling, discovery and development of novel high affinity radio-theranostic antibodies targeting B7-H3, discovery and development of novel PET imaging agents for interrogation of inflammation, innate immunity, and myeloperoxidase (MPO) activity in vivo with first-in-human studies; genetically-encoded reporters for bioluminescence, PET, and SPECT imaging; high throughput screening with siRNA and small molecule libraries to functionalize the genome; cell-penetrating activatable near-infrared fluorescent peptides for imaging; therapeutic cell-penetrating peptides; mechanisms and regulation of the ATP-binding cassette (ABC) superfamily of transporter proteins; radio-pharmaceutical chemistry; medicinal utility of metal complexes

Education & Training

Degree-Granting Education

1984	Duke University, Durham, North Carolina, US, MD
1984	Duke University, Durham, North Carolina, US, Cell Physiology, Ph.D
1978	Stanford University, Palo Alto, California, US, Mechanical Engineering, BS

Postgraduate Training

1987-1988	Fellow, Magnetic Resonance Imaging, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts
1986-1987	Chief Resident, Diagnostic Radiology, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts
1984-1984	Postdoctoral Research Fellow, Physiology, Duke University Medical Center, Durham, North Carolina
1984-1986	Residency, Diagnostic Radiology, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts

Licenses & Certifications

1994	Missouri License
1988	Diplomat American Board of Radiology
1985	Diplomat National Board of Medical Examiners
1984	Massachusetts License

Experience & Service

Faculty Academic Appointments

Adjunct Professor, Department of Radiology, Mallinckrodt Institute of Radiology, Washington University Medical School, St. Louis, MO, 2013 - 2014

Professor, Department of Cell Biology & Physiology, Washington University Medical School, St. Louis, MO, 2010 - 2013

Professor, Department of Developmental Biology, Washington University Medical School, St. Louis, MO, 2008 - 2013

Professor, Department of Molecular Biology & Pharmacology (2008, department renamed), Washington University Medical School, St. Louis, MO, 1998 - 2008

Professor, Department of Radiology, Washington University Medical School, St. Louis, MO, 1998 - 2013

Associate Professor, Department of Radiology (tenured), Washington University Medical School, St. Louis, MO, 1994 - 1998

Associate Professor, Department of Molecular Biology & Pharmacology, Washington University Medical School, St. Louis, MO, 1994 - 1998

Associate Professor, Department of Radiology, Harvard Medical School, Boston, MA, 1993 - 1994

Assistant Professor, Department of Radiology, Harvard Medical School, Boston, MA, 1990 - 1993

Instructor, Department of Radiology, Harvard Medical School, Boston, MA, 1988 - 1990

Administrative Appointments/Responsibilities

Director Ad Interim, Department of Center for Advanced Biomedical Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2020

Executive Director, Quantitative Imaging Analysis Core (QIAC), Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

Department Chair, Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

Deputy Division Head, Department of Research Affairs, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2021

Director, Department of Imaging Sciences Program (ISP), and Principle Investigator T32 ISP Training Grant, Washington University Medical School, St. Louis, MO, 2010 - 2013

Director, Department of BRIGHT Institute, Washington University Medical School, St. Louis, MO, 2010 - 2013

Director, Department of Molecular Imaging Center, Washington University Medical School, St. Louis, MO, 2000 - 2013

Other Professional Positions

Consultantship, AbbVie, 2025 - Present

Member, Scientific Advisory Council, American Association for Cancer Research, 2025 - Present

Consultantship, RadioPharm Theranostics, Ltd, Melbourne, 2023 - 2024

Member, O'Donnell Award, Medicine Committee, TAMEST, 2023 - 2024

Member, Physician-Scientist Award Committee, Damon-Runyon Cancer Research Foundation, New York, NY, 2019 - Present

Member, Awards Committee, World Molecular Imaging Society, Culver City, CA, 2018 - 2019

Member, Publications Committee, American Association for Cancer Research, Philadelphia, PA, 2018 - 2021

Member, Science Policy and Government Affairs Committee, American Association for Cancer Research, Philadelphia, PA, 2017 - 2020

Member, Task Force on Biomedical Sciences, Department of Energy, Secretary of Energy Advisory Board, Washington, DC, 2016 - 2016

Member, External Advisory Board, NIH Training Grant, Case Western Reserve University, Cleveland, OH, 2016 - 2020

Consultantships, Avaant Imaging Ltd, London, UK, 2014 - 2015

Member, Scientific Advisory Board, V Foundation, Cary, NC, 2013 - Present

Member, External Advisory Board, Case Western Reserve Comprehensive Cancer Center, Cleveland, OH, 2013 - 2024

Senior Leadership Committee, Siteman Cancer Center, Washington University Medical School, St. Louis, MO, 2012 - 2013

Member, Scientific Advisory Committee, UC San Diego Moores Comprehensive Cancer Center, San Diego, CA, 2012 - 2024

Director, Oncological Imaging Program, Siteman Cancer Center, Washington University Medical School, St. Louis, MO, 2012 - 2013

Member, External Scientific Advisory Board, Duke Cancer Institute, Durham, NC, 2012 - Present

Member, External Advisory Board, Duke University Comprehensive Cancer Center, Durham, NC, 2010 - 2012

Steering Committee, Washington University Medical School, Molecular Cell Biology Program, St. Louis, MO, 2010 - 2013

Member, Award Committee Panel, Damon-Runyon Cancer Research Foundation, Clinical Investigator Award, New York, NY, 2010 - 2018

Member, Radiological Sciences Executive Committee, Mallinckrodt Institute of Radiology, Washington University Medical School, St. Louis, MO, 2009 - 2013

Member, External Advisory Board, University of Texas Health Science Center at Houston, Institute of Molecular Medicine, Houston, TX, 2009

Member, External Advisory Board, Department of Experimental Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2011

Member, External Advisory Board, University of Arizona Comprehensive Cancer Center, Tucson, AZ, 2008 - 2014

Member, External Advisory Board, Winship Cancer Institute at Emery University, Atlanta, GA, 2007 - 2009

Member, External Advisory Board, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, 2007 - 2009

Consultantships, Ansata Therapeutics, San Diego, CA, 2004 - 2006

Consultantships, Bristol Myers Squibb, Molecular Imaging Program, New York, NY, 2000 - 2005

Consultantships, Eli Lilly and Co, Indianapolis, IN, 1997 - 1999

Co-Chair, Developmental Therapeutics Focus Group, Washington University Cancer Center Program, St. Louis, MO, 1996

Co-Chair, Innovation Strategic Task Force, Mallinckrodt Institute of Radiology, St. Louis, MO, 1996

Member, Research Committee, Mallinckrodt Institute of Radiology, Washington University Medical School, St. Louis, MO, 1994 - 2009

Radiologist, Mallinckrodt Institute of Radiology, Washington University Medical School, St. Louis, MO, 1994 - 2013

Member, Research Resident Selection Committee, Mallinckrodt, Institute of Radiology, Washington University Medical School, St. Louis, MO, 1994 - 2004

Staff Radiologist, Mallinckrodt Institute of Radiology, Abdominal Imaging Division, St. Louis, MO, 1994 - 2005

Consultantships, Vertex Pharmaceuticals, Boston, MA, 1993 - 1995

Consultantships, Salutar/Nycomed Inc, Sunnyvale, CA, 1991 - 1993

Consultantships, Dupont Pharma, North Billerica, MA, 1990 - 1992

Member, Resident Selection Committee, Department of Radiology, Brigham and Women's Hospital, Boston, MA, 1989 - 1994

Member, Radiation Safety Committee, Brigham and Women's Hospital, Boston, MA, 1988 - 1994

Staff Radiologist, Brigham and Women's Hospital, Thoracic and Magnetic Resonance Imaging Divisions, Department of Radiology, Boston, MA, 1988 - 1994

Associate Radiologist, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, 1988 - 1994

Member, Radioactive Drug Research Committee, Brigham and Women's Hospital, Boston, MA, Boston, MA, 1988 - 1994

Institutional Committee Activities

Board Member, Internal Advisory Board (IAB) - Brain Cancer SPORE, 2022 - Present

Member, Science Faculty Recognition Award Committee, 2018 - Present

Member, Operational Priorities Committee #6, Financial Sustainability Working Group, 2017 - Present

Member, Operational Priorities Committee #2, Decisive Discoveries Working Group, 2017 - Present

Co-Chair, MDACC Cancer Center Support Grant, Radiation Oncology Cancer Imaging Program (ROCIP) Steering Committee, 2017 - 2024

Member, Committee of Science Chairs, 2017 - Present

Director ad interim, Center for Advanced Biomedical Imaging (CABI) Executive Steering Committee, 2016 - Present

Member, Brain Metastasis Program Committee, 2016 - Present

Member, Research Residency Program, Selection Committee, Division of Diagnostic Imaging, 2015 - 2021

Co-Chair, Diagnostic Discovery and Development Committee, 2015 - 2016

Co-Chair, SpinLab Steering Committee, Division of Diagnostic Imaging, 2015 - Present

Co-Director, Advanced Scholars Program, Division of Diagnostic Imaging, 2015 - 2020

Member, Institutional Translational Research Review Committee, 2014 - Present

Member, Institutional Physician-Scientist Program Committee, 2014 - Present

Chair, Research Functional Committee, Division of Diagnostic Imaging, 2014 - Present

Member, Strategic Planning Committee, 2014 - 2015

Member, Chair Search Committee, Department of Thoracic & Cardiovascular Surgery, 2014

Member, Diagnostic Imaging Executive Committee (DIEC), 2013 - Present

Member, Institutional Research Executive Committee (IREC), 2013 - 2017

Executive Director, Quantitative Imaging Analysis Core (QIAC) Steering Committee, 2013 - Present

Member, VP Science Steering Committee, 2013 - 2017

Member, Center for Advanced Biomedical Imaging (CABI) Executive Steering Committee, 2013 - Present

Honors & Awards

2015	Joseph D. Bast Keynote Lecture, University of Kansas
2015	President's Award, The University of Texas MD Anderson Cancer Center
2014	Elected Member, Texas Academy of Medicine, Engineering, Science and Technology
2014	Elected Fellow, American Association for the Advancement of Science
2014	Elected Member, National Academy of Medicine
2014	Faculty STARS, Science and Technology Acquisition and Retention Award, University of Texas
2012	Elected Fellow, World Molecular Imaging Society
2011	The Chauncey Leake Lectureship, University of Texas Medical Branch, Galveston, TX
2010	The Alfred P. Fishman Lecture, University of Pennsylvania, Philadelphia, PA
2009	Louis V. Avioli Bone Research Seminar, Washington University Medical School, St. Louis, MO
2009	Distinguished Alumnus Award, Brigham and Women's Hospital, Harvard Medical School, Department of Radiology, Boston, MA
2008	Distinguished Alumnus Award, Duke University Medical School, Durham, NC
2007	National Cancer Policy Forum Speaker, Institute of Medicine, The National Academies, Washington, DC
2007	Chandran Distinguished Lecturer, Duke University, Pratt School of Engineering, Durham, NC
2006	J. Buren Sidbury Distinguished Lecturer, Duke University Medical School, Durham, NC
2005	President's Distinguished Lecturer, Memorial Sloan-Kettering Cancer Center
2005	Lifetime Achievement Award, Society for Molecular Imaging
2004	Annual John Doppman Memorial Lecture, U.S. National Institutes of Health Clinical Center, Bethesda, MD
2002 - 2004	Recognition for Excellence in Mentoring Award, Graduate Student Senate, Washington University, St. Louis, MO
2002	Annual Moreton Memorial Lecture, American College of Radiology, Miami, FL
2001	Annual Wendell G. Scott Lecture, Mallinckrodt Institute of Radiology, St. Louis, MO
2001	Pfahler Memorial Lecturer, Philadelphia Roentgen Ray Society
1995	Award of Merit, Journal of Nuclear Medicine, Society of Nuclear Medicine, Overall Excellence Paper
1993	Fogarty Distinguished Lectureship, U.S. National Institutes of Health, Nuclear Medicine Division
1992	Award of Merit, Journal of Nuclear Medicine, Society of Nuclear Medicine, Best Basic Science Paper
1992 - 1997	Established Investigator, The American Heart Association
1990	Stauffer Award, Association of University Radiologists
1989 - 1990	Whitaker Research Scholar, Harvard Medical School
1989 - 1991	Research Scholar, Radiological Society of North America
1980	Alpha Omega, Alpha Medical Honor Society
1978	Medical Scientist Training Program, Predoctoral Fellowship Award
1977	Tau Beta Pi, Engineering Honor Society

Professional Memberships

National Academy of Medicine

2014 - Present

World Molecular Imaging Society

2012 - Present

American Association for Cancer Research-SNMMI

2011 - 2015

Institute of Medicine of the National Academies of Science

2007

American Association for Cancer Research, Molecular Diagnostics in Cancer

2006 - 2008

American College of Radiology

2004

Society for Molecular Imaging

2000 - 2011

American Chemical Society

1999 - Present

Washington University Medical School, Medical Scientist Training Program (MSTP)

1998 - 2009

Three International Radiopharmaceutical Symposia

1997 - 1999

Siteman Cancer Center, Washington University

1997 - 2006

Washington University-American Cancer Society

1996 - 2011

American Association for the Advancement of Science

1995

American Association for Cancer Research

1992 - Present

Society of Nuclear Medicine

1989 - Present

Association of University Radiologists

1988 - Present

Radiological Society of North America

1988 - Present

American Medical Association

1984 - Present

Selected Presentations & Talks

National Presentations

2025. Early Stage Cancer Detection: Non-Invasive Imagining. Invited. Philadelphia, PA, US.
2024. Radioligand Therapys, Inaugural "Frontiers in Cancer" Scientific Symposium. Invited. Long Island, NY, US.
2019. Intravital Imaging of MPO Activity in Tumor Models. Invited. Imaging Science and Cancer Biology Symposium. Frederick, MD, US.
2019. Quantitative Imaging Analysis Core: Connections and Expansion. Invited. Global Academic Programs. Houston, TX, US.
2019. [18F] FAZA PET/CT as a Biomarker for Monitoring Targeted Therapy. Invited. NCI Brain SPORE Annual Conference. Los Angeles, CA, US.
2017. Concepts and Trends in Advanced Imaging of Breast Cancer. Conference. Breast Cancer Symposium. Washington, DC, US.
2017. Bioluminescent Reporter Screens: Illuminating Novel Regulators and Dynamics of Signaling Pathways. Invited. Triangle Imaging Symposium. Chapel Hill, NC, US.
2016. Molecular Imaging: Illuminating Cancer Biology In Vivo. Invited. Rice-MDACC Research Symposium. Houston, TX, US.
2016. Imaging Genomics and Cancer Systems in Vivo. Invited. Proceedings of the American Association for Cancer Research (AACR) Annual Meeting. New Orleans, LA, US.
2016. Clinical Database and the Potential for Imaging Analytics/Radiogenomics. Invited. Proceedings of the American Association for Cancer Research (AACR) Annual Meeting. New Orleans, LA, US.
2016. Illuminating Cancer Systems with Imaging Reporters. Invited. Cancer Center Annual Retreat. Tucson, AZ, US.
2015. Illuminating Signal Transduction and Metabolic Stress In Vivo. Invited. Case Center for Imaging Research Anniversary Symposium. Cleveland, OH, US.
2015. Molecular Imaging Strategies for Dynamic High Throughput Screens. Invited. National Cancer Institute. Frederick, MD, US.
2015. Illuminating DNA Damage Response and Metabolic Stress In Vivo. Invited. Radiation Research Society. Weston, FL, US.
2015. Illuminating Cancer Systems with Genetically Engineered Mouse Models and Coupled Luciferase Reporters In Vivo. Invited. Biology of Cancer. Cold Spring Harbor, NY, US.
2014. Illuminating Cancer Systems with Genetically Engineered Mouse Models and Coupled Luciferase Reporters. Invited. Molecular Biology in Clinical Oncology Workshop. Aspen, CO, US.
2014. Single Cell Resolution Imaging of Apoptosis In Vivo Using Cell-Penetrating Caspase-Activatable Peptides. Invited. Rice University. Houston, TX, US.
2014. Molecular Imaging of Lung Cancer: Challenges of Tumor Heterogeneity. Invited. Scanlon Lecture. San Antonio, TX, US.
2013. Preclinical Prediction of Tumor Response: Optical Imaging Strategies for Probing Signal Transduction Pathways In Vivo. Invited. San Antonio Breast Cancer Annual Symposium. San Antonio, TX, US.
2013. Illuminating Cancer Systems with Genetically Engineered Mouse Models and Coupled Luciferase Reporters In Vivo. Invited. American Chemical Society. Dallas, TX, US.
2013. Strategies for Imaging Signal Transduction in Tumors and the Tumor Microenvironment. Invited. National Institutes of Health. Rockville, MD, US.
2013. Cancer Genomic and Systems Heterogeneity. Invited. American Association for Cancer Research. San Diego, CA, US.
2013. Imaging Tumor Response: Challenges of Heterogeneity. Invited. American Society for Radiation Oncology. Orlando, FL, US.
2012. Molecular Imaging Strategies. Invited. American Association for Cancer Research. Boston, MA, US.
2012. Cancer Genomic and Systems Heterogeneity: Characterization and Challenges. Invited. Imaging in 2020 Meeting. Jackson Hole, WY, US.
2012. Reporter Imaging in Cancer Biology and Therapy. Invited. American Association for Cancer Research. Chicago, IL, US.
2011. Cerenkov Radiation Energy Transfer (CRET) Imaging. Invited. Society of Nuclear Medicine Annual Meeting. San Antonio, TX, US.
2011. Meet-the-Expert session, Advances in Dynamic Real-Time Molecular Imaging of Signaling Pathways: Monitoring Protein-Protein Interactions, Protein Processing, and Drug Action In Vivo. Invited. American Association for Cancer Research. Orlando, FL, US.
2011. Clinical and Translational Sciences Provocative Questions Workshop. Invited. National Cancer Institute, National Institutes of Health. Bethesda, MD, US.
2010. Bioluminescence Imaging of Signal Transduction Pathways in Live Mice. Invited. American Heart Association. Palm Springs, CA, US.
2010. PET/SPECT Imaging of Multidrug Resistant P-glycoprotein: Transport Activity Monitoring Associated with Blood- Brain-Barrier Function. Invited. National Institutes of Health. Bethesda, MD, US.
2010. Issues and Challenges Related to Imaging. Invited. American Association for Cancer Research. San Francisco, CA, US.
2009. Caspase 3 and Myeloperoxidase Activities as Optical Imaging Targets In Vivo. Invited. National Institutes of Health Workshop: Optical Diagnostic and Biophotonic Methods from Bench to Bedside. Bethesda, MD, US.
2009. Molecular Imaging: Real-Time Imaging of Signal Transduction Pathways and Targeted Drug Action In Vivo. Invited. American Society for Therapeutic Radiology and Oncology Meeting. St. Louis, MO, US.
2009. Molecular Imaging: Real-Time Imaging of Signal Transduction Pathways and Targeted Drug Action in Living Animals. Invited. American Association for Cancer Research. Aspen, CO, US.
2009. Molecular Imaging of Cancer Pathways In Vivo. Invited. American Association for Cancer Research. Denver, CO, US.
2008. Dynamic Molecular Imaging of Signal Transduction Pathways In Vivo. Invited. San Antonio Breast Cancer Symposium 2008. San Antonio, TX, US.
2008. Dynamic Imaging of Signal Transduction Pathways and Drug Pharmacodynamics In Vivo. Invited. National Institutes of Health - American Association for Cancer Research. National Harbor, MD, US.
2008. Dynamic Molecular Imaging of Signal Transduction Pathways in Discovery Research. Invited. Roswell Park Cancer Institute. Buffalo, NY, US.
2008. Dynamic Imaging of Signal Transduction Pathways and Target-Specific Drug Pharmacodynamics In Vivo. Invited. Drug Carriers in Medicine & Biology. Big Sky, MT, US.
2008. Dynamic Molecular Imaging of Signal Transduction Pathways In Vivo. Invited. American Association for Cancer Research. Monterey, CA, US.
2008. Real-Time Molecular Imaging of Signal Transduction Pathways In Vivo. Invited. Era of Hope Breast Cancer Research Meeting. Baltimore, MD, US.
2007. Cancer Clinical Trials Workshop, Molecular Imaging Strategies in Drug Development. Invited. Institute of Medicine. Washington, DC, US.
2007. Strategies to Probe Signal Transduction in Immune Response In Vivo. Invited. Imaging Immune Responses. Keystone, CO, US.
2006. Genetically-Encoded Reporters for Imaging Cancer Metastasis. Invited. Cancer and Bone Society. San Antonio, TX, US.
2006. Real-Time Molecular Imaging of Signal Transduction In Vivo. Invited. American Association for Cancer Research. San Francisco, CA, US.
2006. Molecular-Genetic Imaging Symposium. Invited. Radiological Society of North America. Chicago, IL, US.
2006. Real-Time Molecular Imaging of Signal Transduction In Vivo. Invited. American Association of Cancer Institutes. Chicago, IL, US.
2006. Molecular Imaging with Activatable Fluorescent Peptides. Invited. American Chemical Society. San Francisco, CA, US.
2006. Molecular Imaging In Vivo with Genetically Encoded Reporters. Invited. American Society of Gene Therapy. Baltimore, MD, US.
2006. Pathway-Specific Molecular Imaging Strategies. Invited. Keystone Symposium: Cancer and Kinases. Santa Fe, NM, US.
2006. Principles of Multimodality Molecular Imaging. Invited. Society of Nuclear Medicine. Tempe, AZ, US.
2005. Molecular-Genetic Imaging Symposium. Invited. Radiological Society of North America. Chicago, IL, US.
2005. Genetically-Encoded Reporter Strategies for Real-Time Imaging of Signal Transduction in Living Animals. Invited. 2005 Summer Research Conference. Aspen, CO, US.
2005. Molecular Imaging of Cancer: Pathways to Patients Symposium, Genetically Encoded Reporters for Imaging Signal Transduction and Protein-Protein Interactions In Vivo. Invited. American Association for Cancer Research. Anaheim, CA, US.
2005. Imaging Cell Trafficking and Protein-Protein Interactions In Vivo. Invited. Gordon Research Conference on Radiation Oncology 2005. Ventura, CA, US.
2004. Genetically-Encoded Reporter Strategies for Imaging Protein Function and Protein-Protein Interactions In Vivo. Invited. Somona Gene Therapy Workshop. Sonoma Valley, CA, US.
2004. High Throughput Strategies for Analysis of Protein-Protein Interactions. Invited. National Cancer Institute. Washington, DC, US.
2004. Genetically-Encoded Reporter Strategies for Imaging Protein Function and Protein-Protein Interactions. Invited. National Institute of Environmental Health Sciences. Smithfield, TX, US.
2004. Reporter Strategies for Imaging Gene Expression and Protein Function In Vivo. Invited. American Society of Nuclear Cardiology. Bethesda, MD, US.
2004. Molecular Imaging. Invited. Oncology Nursing Society and American Association for Cancer Research. Anaheim, CA, US.
2004. Strategies for Molecular Imaging In Vivo. Invited. Radiation Research Society. St. Louis, MO, US.
2004. Reporter Strategies for Imaging Protein-Protein Interactions In Vivo. Invited. 52nd Annual Meeting. San Francisco, CA, US.
2004. Reporter Strategies in Molecular Imaging. Invited. IEEE International Symposium on Biomedical Imaging. Washington, DC, US.
2004. Strategies in Molecular Imaging. Invited. American Association for Cancer Research. Orlando, FL, US.
2004. Fusion Reporter Strategies in Molecular Imaging. Invited. Radiological Society of North America. Bethesda, MD, US.
2003. Strategies in Molecular Imaging. Invited. American Liver Foundation. Boston, MA, US.
2003. Molecular Imaging of Gene Expression In Vivo. Invited. American College of Radiology. Washington, DC, US.
2003. Molecular Imaging. Invited. New England Roentgen Ray Society. Boston, MA, US.
2003. Molecular Imaging. Invited. National Academy of Sciences, Institute of Medicine. Washington, DC, US.
2002. Molecular Imaging of Gene Expression. Invited. Council for Advancement of Science Writing 40th Symposium: New Horizons in Science. St. Louis, MO, US.
2002. Molecular Imaging of MDR. Invited. Society of Nuclear Medicine. Kansas City, MO, US.
2002. Oncologic Molecular Imaging. Invited. Philips Medical Systems/Society for Molecular Imaging Media Roundtable. New York, NY, US.
2002. Molecular Imaging in Radiological Practice. Invited. American College of Radiology. Miami, FL, US.
2002. Molecular Imaging of MDR and p53. Invited. Society for Molecular Imaging. Boston, MA, US.
2002. Imaging MDR and p53. Invited. Society of Nuclear Medical. Los Angeles, CA, US.
2002. Molecular Imaging in Cancer Trials. Invited. American Society of Clinical Oncologists. Orlando, FL, US.
2002. Molecular Imaging. Invited. Federation of American Societies for Experimental Biology. New Orleans, LA, US.
2002. Workshop: Imaging Gene Expression In Vivo II. Invited. U.S. Department of Energy. Boston, MA, US.
2002. Permeation Peptides. Invited. U.S. National Institutes of Health. Rockville, MD, US.
2002. Special Conference on Molecular Imaging in Cancer. Invited. American Association for Cancer Research. Orlando, FL, US.
2001. Workshop on National Institute of Biomedical Imaging and Bioengineering. Invited. RSNA/ARR/AAPM. Washington, DC, US.
2001. Molecular Imaging with PET and SPECT. Invited. Imaging 2020. Jackson Hole, WY, US.
2001. Strategies for Molecular Imaging in Oncology. Invited. U.S. National Institutes of Health. Bethesda, MD, US.
2001. Target Selection: Molecular Imaging Strategies. Invited. U.S. National Institutes of Health. Bethesda, MD, US.
2001. ABC Transporters in Disease. Invited. American Society of Clinical Pharmacology and Therapeutics 102nd Annual Meeting. Orlando, FL, US.
2001. Molecular Imaging. Invited. American College of Radiology and AdMeTech. San Diego, CA, US.
2001. Metals in Molecular Imaging. Invited. Gordon Conference. Ventura, CA, US.
2000. Pharmacokinetic Analysis of Multidrug Resistance. Invited. Society for Nuclear Imaging in Drug Development Meeting. Bethesda, MD, US.
2000. Molecular Imaging in Cancer. Invited. American Society of Clinical Oncologists. New Orleans, LA, US.
2000. Molecular Imaging Symposium. Invited. Association of University Radiologists. Orlando, FL, US.
2000. Molecular Nuclear Medicine. Invited. 21st High Country Nuclear Medicine Conference. Vail, CO, US.
2000. Workshop for Early Detection of Breast Cancer. Invited. National Academy of Sciences. Washington, DC, US.
1999. In Vivo Molecular Imaging. Invited. Creative Concepts Conference. Vail, CO, US.
1999. Drug Efflux Pumps. Invited. American Association of Pharmaceutical Scientists Annual Meeting. New Orleans, LA, US.
1999. Experimental Design for Laboratory Investigation. Invited. Radiological Society of North America. Washington, DC, US.
1999. Imaging Multidrug Resistance. Invited. Society of Nuclear Medicine. Chicago, IL, US.
1999. Pediatric Oncology: Functional Imaging of Multidrug Resistance. Invited. Society of Nuclear Medicine. Los Angeles, CA, US.
1999. Membrane Transporters and Drug Therapy. Invited. National Institutes of Health Frontiers Symposium. Bethesda, MD, US.
1999. Imaging the Chemistry of Cancer. Invited. 1999 Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy. Orlando, FL, US.
1999. Multidrug Resistance in Therapy and Diagnosis. Invited. American College of Nuclear Physicians Annual Meeting. Kona, HI, US.
1998. Characterizing Drug Specificity by Pharmacokinetic Analysis in Gene Knockout Mice. Invited. Society for Nuclear Imaging in Drug Development Meeting. Bethesda, MD, US.
1998. Experimental Design for Laboratory Investigation. Invited. Grantsmanship Workshop. Washington, DC, US.
1997. Radiopharmaceutical Development: Functional Imaging of Multidrug Resistance. Invited. 44th Annual Meeting. San Antonio, TX, US.
1996. Molecular Biology Techniques Applied to Radiopharmaceutical Discovery. Invited. 43rd Annual Meeting. Denver, CO, US.
1995. P-glycoprotein at the Blood-Brain Barrier. Invited. Invited Poster/Lecture. Los Angeles, CA, US.
1995. Challenges of Radiolabeled Antisense Probes. Invited. 9th International Symposium. Ann Arbor, MI, US.
1994. Scholars Research Symposium. Invited. Radiological Society of North America. San Francisco, CA, US.
1994. Cancer Receptor Imaging Research Symposium. Invited. U.S. National Institutes of Health, National Cancer Institute. Washington, DC, US.
1993. Molecular Nuclear Medicine Symposium. Invited. American College of Nuclear Physicians/U.S. Department of Energy. Washington, DC, US.
1993. Contrast Agent Research Symposium. Invited. U.S. National Institutes of Health, National Cancer Institute. Washington, DC, US.
1992. Wintergreen Myocardial Perfusion Imaging Research Symposium. Invited. Wintergreen, VA, US.
1990. Myocardial Perfusion Imaging Research Symposium. Invited. Boca Raton, FL, US.

International Presentations

2024. Anti-Cancer Immune Activation with Beta-Radioligand Therapy and Selective Targeting of the 4Ig Isoform of B7-H3. Invited. International Conference on Tumor Microenvironment and Cellular Stress (TMCS2024), CY.
2023. Isoform-Selective Targeting of 4Ig-B7-H3 for PET Imaging and Beta-Radioligand Therapy. Invited. Internal Conference on Advanced Biomedical Sciences (ICABS). Taichung, TW.
2016. Illuminating Cancer Systems with Imaging Reporters: p53 deficiency and metastatic potential in PDX models of triple negative breast cancer. Invited. Proceedings of the 16th Biennial Congress of the Metastasis Research Society. Chendgu, CN.
2016. Illuminating Cancer Systems with Imaging Reporters. Invited. 28th Lorne Cancer Conference. Lorne, AU.
2016. Opportunities in the Landscape of Quantitative and Molecular Imaging. Invited. UHN Princess Margaret Cancer Conference. Toronto, CA.
2015. Of Mice and Men: Mapping the Landscape of Murine Models in Molecule Imaging. Invited. World Molecular Imaging Congress. Honolulu, US.
2015. QIAC: An Infrastructure for Managing Imaging Biomarker Data. Invited. World Molecular Imaging Congress. Honolulu, US.
2015. Illuminating Inflammation and Metabolic Stress In Vivo. Invited. CIHR-STP Cancer Research and Technology Transfer (CaRTT) London Regional Cancer Centre. London, CA.
2014. Illuminating Immune Response with Bioluminescence Imaging In Vivo. Invited. CMUH/MDACC Joint Cancer Symposium. Taichung, TW.
2010. Introduction to Reporter Genes. Invited. World Molecular Imaging Congress. Kyoto, JP.
2009. Imaging Signal Transduction Pathways and Targeted Drug Action In Vivo. Invited. American Association for Cancer Research. Boston, US.
2009. Introduction to Reporter Genes. Invited. World Molecular Imaging Congress. Montreal, CA.
2009. Multi-Modality Genetically-Encoded Imaging Reporters. Invited. Society of Radiopharmaceutical Sciences. Edmonton, CA.
2009. Imaging Signature Molecules and their Interactions in the Body. Invited. American Thoracic Society. Lucerne, CH.
2008. Real-Time Molecular Imaging of Signal Transduction Pathways In Vivo. Invited. American Association for Cancer Research. Jerusalem, IL.
2008. Optical In Vitro Molecular Imaging Assays. Invited. World Molecular Imaging Congress. Nice, FR.
2007. Dissecting Signal Transduction Pathways in Vivo with Dynamic Molecular Imaging. Invited. American Association for Cancer Research. Singapore, SG.
2006. Molecular Imaging Strategies to Assess Signal Transduction and Protein-Protein Interactions Non-invasively. Invited. EORTC-NCI-AACR International Symposium. Prague, CZ.
2006. Spying on Cancer with Genetically Encoded Imaging Reporters. Invited. National Cancer Research Institute. Birmingham, GB.
2003. Molecular Imaging. Invited. Ernst Schering Research Foundation 49th Workshop. Berlin, DE.
2002. Molecular Imaging of p53. Invited. National Cancer Institute International Workshop. Frankfurt, DE.
2002. Molecular Imaging of MDR. Invited. American Association of Pharmaceutical Scientists Annual Meeting. Toronto, CA.
2000. Photonics in Imaging Gene Expression. Invited. 8th International Mind Brain Conference. Hamamatsu City, JP.
1998. Nuclear Medicine Applications of Molecular Biology Techniques. Invited. 45th Annual Meeting. Toronto, CA.
1997. Imaging Multidrug Resistance. Invited. 10th International Symposium. Rapallo, IT.
1996. Oncological Applications of Technetium-99m Agents. Invited. 5th International Conference. Lyon, FR.

Formal Peers

2024. Chemistry-Biology Interface Training Program (CBITP). Invited. Urbana, IL, US.
2019. 18F] FAZA PET/CT for Monitoring Oxygen Sensing In Vivo. Invited. Cincinnati, OH, US.
2019. Strategies in Molecular Imaging: Illuminating Signaling Pathways In Vivo. Invited. Houston, TX, US.
2018. [18F] FAZA PET/CT for Monitoring Targeted Modulation of Oxidative Phosphorylation In Vivo. Invited. Cambridge, GB.
2018. [18F] FAZA PET/CT for Monitoring Targeted Modulation of Oxidative Phosphorylation In Vivo. Invited. Houston, TX, US.
2018. [18F]FAZA PET/CT for Monitoring Targeted Modulation of Oxidative Phosphorylation In Vivo. Invited. San Francisco, CA, US.
2018. Advances in Cancer Imaging. Invited. Houston, TX, US.
2017. Illuminating Cancer Systems with Genetically Engineered Mouse Models and Coupled Luciferase Reporters. Invited. Houston, TX, US.
2017. Illuminating Biology In Vivo with Genetically-Encoded Bioluminescent Reporters. Invited. Houston, TX, US.
2016. Bioluminescent Reporter Screens: Illuminating Novel Regulators and Dynamics of Signaling Pathway. Invited. Houston, TX, US.
2016. Bioluminescent Reporter Screens: Illuminating Novel Regulators and Dynamics of Signaling Pathways. Invited, Cambridge, GB.
2016. High Throughput Bioluminescent Reporter Screens: Illuminating Novel Regulators of Signaling Dynamics. Invited. Houston, TX, US.
2016. Molecular Imaging Strategies. Invited. Houston, TX, US.
2015. Of Mice and Men: Opportunities in the Landscape of Quantitative and Molecular Imaging. Invited. Houston, TX, US.
2015. Opportunities in the Landscape of Quantitative and Molecular Imaging. Invited. Houston, TX, US.
2015. Molecular Imaging Strategies for Dynamic High Throughput Screens. Invited. Frederick, MD, US.
2015. Illuminating Signaling Pathways and Metabolic Stress In Vivo. Invited. Houston, TX, US.
2015. High throughput imaging strategies for interrogation of biology in vivo and other thoughts. Invited. Kansas City, KS, US.
2015. Illuminating Signaling Pathways and Metabolic Stress In Vivo. Invited. New York, NY, US.
2015. Molecular Imaging Strategies for Dynamic High Throughput Screens. Invited. Houston, TX, US.
2015. Molecular imaging of Signal Transduction and Metabolic Stress In Vivo. Invited, US.
2015. Illuminating Signaling Pathways and Metabolic Stress In Vivo. Invited. Philadelphia, PA, US.
2014. Illuminating Signalling Pathways and Metabolic Stress In Vivo. Invited. Houston, TX, US.
2014. Multi-Scale Interrogation of Signaling Pathways with Bioluminescence Imaging. Invited. Houston, TX, US.
2014. Illuminating Metabolic Stress and Cancer Metabolism In Vivo. Invited. Houston, TX, US.
2014. Tumor Heterogeneity: Impact on Molecular Imaging. Invited. Houston, TX, US.
2014. Potential Collaborations in Imaging and Image Analysis. Invited. Houston, TX, US.
2014. Tumor Heterogeneity: Impact on Molecular Imaging. Invited. Houston, TX, US.
2014. Generically-Encoded Reporters for Imaging Protein Processing and Signal Transduction In Vivo. Invited. Houston, TX, US.
2014. Quantitative Imaging Analysis Core (QIAC). Invited. Houston, TX, US.
2014. Generically-Encoded Reporters for Imaging Signal Transduction In Vivo. Invited. Houston, TX, US.
2013. Opportunities for Research and Training in Dynamic Analysis of Cancer In Vivo. Invited. South Bend, IN, US.
2013. Imaging Signaling Pathways and Protein Function In Vivo: Single Cells to Systems. Invited. Houston, TX, US.
2013. Opportunities for Dynamic Analysis of Pancreatic Cancer In Vivo. Invited. Houston, TX, US.
2013. Cancer Genomic and Systems Heterogeneity. Invited. Worchester, MA, US.
2013. Cancer Genomic and Systems Heterogeneity: Characterization and Challenges. Invited. Nashville, TN, US.
2012. Functional Genomics and High Throughput Discovery Research. Invited. Durham, NC, US.
2012. Molecular Imaging Strategies for Dynamic Analysis of Systems. Invited. Portland, OR, US.
2012. Reporter Strategies for Imaging Drug and Radiation Response In Vivo. Invited. New York, NY, US.
2012. Dynamic Molecular Imaging: Proximity Sensing and Protein Processing in Real-Time. Invited. Tucson, AZ, US.
2011. Molecular Imaging Strategies for Dynamic Analysis of Systems. Invited. Ithaca, NY, US.
2011. Real-Time Molecular Imaging Strategies for Investigating Microbial Pathogenesis. Invited. Louisville, KY, US.
2011. Molecular Imaging of PI3K/AKT/mTOR Signaling In Vivo. Invited. Orlando, FL, US.
2011. Proximity Sensing with Molecular Imaging In Vivo: Proteins, Peptides and PET Isotopes. Invited. St. Louis, MO, US.
2011. Proximity Sensing: Real-Time Imaging of Protein-Protein Interactions and Protein Processing In Vivo. Invited. Galveston, TX, US.
2010. Dynamic Real-Time Molecular Imaging of Signaling Pathways In Vivo: Protein Processing, Proximity Sensing, and Drug Action. Invited. Cambridge, MA, US.
2010. Multi-Color Strategies for Imaging Signal Transduction Pathways In Vivo. Invited. Cambridge, MA, US.
2010. Molecular Imaging and High Throughput Screening. Invited. St. Louis, MO, US.
2010. Molecular Imaging and High Throughput Screening Applications to Microbial Pathogenesis. Invited. St. Louis, MO, US.
2010. Dynamic Molecular Imaging of NFkB Signal Transduction and Inflammation In Vivo. Invited. Philadelphia, PA, US.
2010. Molecular Imaging of Signal Transduction Pathways and Anti-Cancer Drug Action In Vivo. Invited. Tampa, FL, US.
2009. Imaging Signal Transduction Pathways and Targeted Drug Action In Vivo. Invited. Guangzhou, CN.
2009. Dynamic Imaging of Molecular Signaling in Live Cells and Animals. Invited. Hong Kong, CN.
2009. Molecular Imaging: Context and Dynamics in Biological Research. Invited. Denver, CO, US.
2009. Real-Time Imaging of Signal Transduction Pathways Using Genetically-Encoded Reporters In Vivo. Invited. Bethesda, MD, US.
2009. Dynamic Molecular Imaging with Activatable and Genetically-Encoded Reporters. Invited. Detroit, MI, US.
2009. Real-Time Imaging of Signal Transduction Pathways and Targeted Drug Action in Living Animals. Invited. La Jolla, CA, US.
2009. Molecular Imaging: Interrogating Signal Transduction Pathways from Bench to Bedside. Invited. Boston, MA, US.
2009. Imaging Signal Transduction Pathways In Vivo. Invited. Memphis, TN, US.
2009. Dynamic Molecular Imaging of Signal Transduction Pathways In Vivo. Invited. Dallas, TX, US.
2009. Real-Time Imaging of Signal Transduction Pathways and Drug Action In Vivo. Invited. Omaha, NE, US.
2009. Molecular Imaging: Multidisciplinary Frontiers in Real-Time Systems Biology. Invited. Durham, NC, US.
2009. Dynamic Molecular Imaging of Signal Transduction Pathways In Vivo. Invited. Amsterdam, NL.
2009. Real-Time Imaging of Signal Transduction Pathways In Vivo. Invited. St. Louis, MO, US.
2008. Optical Imaging of Apoptosis In Vivo with NIRF Probes. Invited. St. Louis, MO, US.
2008. Real-Time Molecular Imaging of Signal Transduction Pathways In Vivo. Invited. New York, NY, US.
2007. Dynamic Imaging of Signal Transduction and Protein-Protein Interactions In Vivo. Invited. Chicago, IL, US.
2007. Real-Time Imaging of Signal Transduction Modulators In Vivo. Invited. Boulder, CO, US.
2007. Real-Time Imaging of Signal Transduction In Vivo. Invited. Baltimore, MD, US.
2007. Real-Time Imaging of Signal Transduction In Vivo. Invited. St. Louis, MO, US.
2007. Real-Time Imaging of Inflammatory Signaling Cascades. Invited. Bethesda, MD, US.
2007. Real-Time Imaging of Signal Transduction and Targeted Drug Action in Living Animals. Invited. Aspen, CO, US.
2007. Real-Time Imaging of Signal Transduction in Living Cells. Invited. Boston, MA, US.
2007. Spectral Deconvolution and Real-Time Imaging of Signal Transduction in Living Cells. Invited. Philadelphia, PA, US.
2007. Spectral Deconvolution of Multi-Color Bioluminescent Reporters for Imaging Signal Transduction in Real-Time. Invited. Durham, NC, US.
2007. Imaging Signal Transduction Pathways in Real-Time. Invited. Iowa City, IA, US.
2007. Spectral Deconvolution of Multi-Color Reporters for Imaging Signal Transduction Pathways in Real-Time. Invited. Stanford, CA, US.
2007. Real-Time Imaging of Signal Transduction Modulators In Vivo. Invited. St. Louis, MO, US.
2007. Real-Time Molecular Imaging of Signal Transduction In Vivo. Invited. San Francisco, CA, US.
2006. Real-Time Imaging of Signal Transduction Modulators In Vivo. Invited. Denver, CO, US.
2006. Functional Imaging of Multidrug Resistance. Invited. Istanbul, TR.
2006. Spying on Biology with Molecular Imaging. Invited. Cleveland, OH, US.
2006. Real Time Imaging of Signal Transduction In Vivo. Invited. Houston, TX, US.
2006. Real Time Imaging of Signal Transduction In Vivo. Invited. Toronto, CA.
2006. Molecular Imaging: Spying on Biology with Genetically Encoded Reporters. Invited. Durham, NC, US.
2005. Small Animal Imaging: Imaging Signal Transduction and Protein-Protein Interactions In Vivo. Invited. Memphis, TN, US.
2005. Imaging Signal Transduction and Protein-Protein Interactions with Genetically Encoded Reporters In Vivo. Invited. Houston, TX, US.
2005. Imaging Signal Transduction and Protein-Protein Interactions with Genetically Encoded Reporters In Vivo. Invited. Boston, MA, US.
2005. Spying on Cancer with Genetically Encoded Imaging Reporters. Invited. Boston, MA, US.
2005. Real-Time Molecular Imaging of Signal Transduction and Protein-Protein Interactions with Genetically Encoded Reporters In Vivo. Invited. Frederick, MD, US.
2005. Imaging Signal Transduction and Protein-Protein Interactions with Genetically Encoded Reporters In Vivo. Invited. St. Louis, MO, US.
2005. Functional Imaging of Multidrug Resistance. Invited. Rosemont, IL, US.
2005. Imaging Signal Transduction and Protein-Protein Interactions In Vivo with Genetically Encoded Reporters. Invited. Nashville, TN, US.
2005. Real-Time Imaging of Signal Transduction and Protein-Protein Interactions in Living Animals. Invited. New York, NY, US.
2004. Reporter Strategies for Imaging Protein Function and Protein-Protein Interactions In Vivo. Invited. Hershey, PA, US.
2004. Molecular Genetic Reporter Strategies for Imaging Protein Function and Protein-Protein Interactions in Living Animals. Invited. Bethesda, MD, US.
2004. Reporter Strategies for Imaging Protein Function and Protein-Protein Interactions in Living Animals. Invited. Los Angeles, CA, US.
2004. Reporter Strategies for Imaging Protein-Protein Interactions In Vivo. Invited. Chevy Chase, MD, US.
2004. Molecular Imaging of Cancer. Invited. St. Louis, MO, US.
2004. Molecular Imaging. Invited. St. Louis, MO, US.
2004. Molecular Imaging. Invited. St. Louis, MO, US.
2003. Imaging Gene Expression and Protein Function In Vivo. Invited. New York, NY, US.
2003. Imaging Gene Expression and Protein Function In Vivo. Invited. Dallas, TX, US.
2003. Molecular Imaging. Invited. St. Louis, MO, US.
2003. Molecular Imaging. Invited. Aspen, CO, US.
2003. Molecular Imaging. Invited. Stanford, CA, US.
2003. Molecular Imaging. Invited. Jackson, MS, US.
2003. Strategies for Molecular Imaging. Invited. Boston, MA, US.
2002. Molecular Imaging. Invited. Houston, TX, US.
2002. Molecular Imaging of Gene Expression with PET and SPECT. Invited. Boston, MA, US.
2002. Molecular Imaging of Gene Expression. Invited. St. Louis, MO, US.
2001. Molecular Imaging. Invited. St. Louis, MO, US.
2001. Molecular Imaging. Invited. Pittsburgh, PA, US.
2001. Molecular Imaging in Cancer. Invited. Philadelphia, PA, US.
2000. Molecular Imaging in Cancer. Invited. San Diego, CA, US.
2000. General Medicine Symposium on Metals in Medicine. Invited. Bethesda, MD, US.
2000. Molecular Imaging in Cancer. Invited. Los Angeles, CA, US.
1999. In Vivo Molecular Imaging. Invited. Toronto, CA.
1999. Workshop: Imaging Gene Expression In Vivo. Invited. La Jolla, CA, US.
1999. Joint Working Group on Quantitative In Vivo Functional Imaging in Oncology. Invited. Arlington, VA, US.
1998. Multidrug Resistance Workshop. Invited. St. Louis, MO, US.
1998. Imaging MDR Gene Expression in Cancer. Invited. St. Louis, MO, US.
1997. Radioisotope-Based Medical Research in the Post-Genome Era: Joint Workshop. Invited. Washington, DC, US.
1997. Multidrug Resistance. Invited. Chicago, IL, US.
1997. Multidrug Resistance. Invited. West Lafayette, IN, US.
1997. Nuclear Oncology Course: From Genotype to Patient Care. Invited. Baltimore, MD, US.
1997. Workshop on Functional Consequences of Gene Expression in Health and Disease. Invited. San Antonio, TX, US.
1997. Functional Imaging of Multidrug Resistance. Invited. Stanford, CA, US.
1997. Functional Imaging of Multidrug Resistance. Invited. Toronto, CA.
1996. Imaging Gene Expression in Cancer: MDR Pgp. Invited. St. Louis, MO, US.
1996. Targeting Multidrug Resistance with Metallopharmaceuticals. Invited. St. Louis, MO, US.
1996. Cancer Targets: Imaging and Multidrug Resistance. Invited. St. Louis, MO, US.
1995. Multidrug Resistance Modulation and Imaging. Invited. Research Triangle Park, NC, US.
1995. Phase I Clinical Trial: Multidrug Resistance Modulation. Invited. Washington, DC, US.
1994. Symposium on Imaging Research Directions. Invited. Washington, DC, US.
1994. Magnetic Resonance Continuing Education Course: MR Contrast Agents. Invited. Boston, MA, US.
1994. Center for Imaging and Pharmaceutical Research. Invited. Charlestown, MA, US.
1993. Fogarty Distinguished Lectureship. Invited. Bethesda, MD, US.
1993. Imaging Multidrug Resistance. Invited. Augusta, GA, US.
1991. Tc-99m-MIBI and Mitochondrial Membrane Potential. Invited. Worchester, MA, US.

Less

Grant & Contract Support

Date:	2025 - 2027
Title:	Decoding the Mechanisms of Response to Systemic Radioligand Therapy (RLT) versus Localized External Beam Radiation Therapy (EBRT)
Funding Source:	NIH/NCI
Role:	Mentor
ID:	R03CA308386

Date:	2025 - 2026
Title:	2022-1029: Companion 18F-Fluoroazomycin Arabinoside ([18F]FAZA) PET/CT Imaging Trial for Treatment Assessment of Evofosfamide (TH-302) in Prostate, Pancreatic, and HPV(-) Head and Neck Tumors
Funding Source:	Immunogenesis
Role:	PI

Date:	2025 - 2030
Title:	Imaging Low Frequency Features of Cell Death
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP22897

Date:	2025 - 2030
Title:	Does Alzheimer's Disease Sensitize Subjects to Chemo-Brain?
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP00023013

Date:	2025 - 2028
Title:	Does Alzheimer’s Disease sensitize subjects to chemo-brain?
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP250362

Date:	2025 - 2028
Title:	Leveraging PD-L1 biology to Develop Next-Generation Theranostics
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP250363

Date:	2025 - 2026
Title:	Harnessing the immune modulatory role of statins and B7-H3 to enhance survival for pediatric LGG patients
Funding Source:	Lindonlight Collective
Role:	Co-I

Date:	2024 - 2029
Title:	Molecular Imaging of Neutrophil Trap Driven Inflammation in Pancreatic Adenocarcinoma
Funding Source:	NIH/NCI
Role:	PI

Date:	2024 - 2025
Title:	NanoScan SPECT 4H / CT1512 / PET122S in-vivo imager
Funding Source:	NIH/NCI
Role:	Major User
ID:	1S10OD036241-01

Date:	2023 - 2024
Title:	Assessment of At-21 Reactivity
Funding Source:	Ionetix Corp/Texas A&M
Role:	Co-I

Date:	2023 - 2027
Title:	OC220021 - Dissecting the Mechanism(s) of Statin-mediated Enhancement of Ovarian Cancer Therapy
Funding Source:	Department of Defense (DOD)
Role:	Other Mentor
ID:	FP00017289

Date:	2023 - 2024
Title:	Fluorescent-Guided Surgery in Ovarian Cancer with apotentially Best-in-Class antibody MIL33B
Funding Source:	The University of Texas MD Anderson Cancer CenterSPORE in Ovarian Cancer
Role:	PI
ID:	P50CA281701

Date:	2023 - 2024
Title:	Exploring statin-mediated changes of B7-H3 dimerization in Ovarian Cancer
Funding Source:	The University of Texas MD Anderson Cancer Center Ovarian Cancer SPORE
Role:	Mentor
ID:	P50CA281701

Date:	2023 - 2025
Title:	Humanized hMIL33B-H3 Fc mutant (aka Betabart) targeting B7H3: Phase 1 clinical trial
Funding Source:	Radiopharm Ventures, LLC
Role:	PI

Date:	2023 - 2025
Title:	First-in-Human Imaging of Innate Immunity Activation with a Redox-Tuned PET Reporter
Funding Source:	NIH/NCI
Role:	PI
ID:	1-R21 CA277283-01

Date:	2023 - 2026
Title:	PET Imaging of Immunotherapy-Induced Adverse Events
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP230238

Date:	2022 - 2027
Title:	Acquired Resistance to Therapy and Iron (ARTI) Center – Molecular Imaging Core
Funding Source:	NIH/NCI
Role:	Core Leader
ID:	U54CA274220

Date:	2022 - 2027
Title:	[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events
Funding Source:	NIH/NCI
Role:	PI
ID:	R01CA273130

Date:	2022 - 2024
Title:	Exploring Statin-Mediated Changes of B7-H3 Dimerization in Glioblastoma
Funding Source:	The University of Texas MD Anderson Cancer Center SPORE in Brain Cancer
Role:	Mentor

Date:	2022 - 2023
Title:	Improving Detection of Neurotoxicity in Immunotherapies QuickFire Challenge
Funding Source:	Johnson & Johnson
Role:	PI
ID:	N/A

Date:	2022 - 2027
Title:	Understanding the Tumor Intrinsic and Extrinsic Roles of B7-H3 Expression in Gynecological Cancer Tumorigenesis
Funding Source:	NIH/NCI
Role:	Mentor
ID:	K99CA263040-01A1

Date:	2022 - 2027
Title:	Image Guided Cancer Therapy Training Program
Funding Source:	NIH/NCI
Role:	Preceptor
ID:	T32CA261856-01A1

Date:	2022 - 2024
Title:	Making it work: From production of astatine-211 to animal studies, via fundamental chemistry
Funding Source:	Texas A&M University / Department of Energy
Role:	Co-I

Date:	2021 - 2026
Title:	An Academic-Industrial Partnership for Preclinical Cancer Studies with NIR-II Fluorescence Imaging: Instrumentation, Contrast Agents and Applications
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP00011944

Date:	2021 - 2025
Title:	PET Imaging of ROS Burst in Immune Adverse Events: First-in-Human Evaluation
Funding Source:	NIH/NCI
Role:	PI
ID:	R01AI165545

Date:	2021 - 2025
Title:	A Novel PARP Inhibitor PET Tracer for Breast Cancer
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	R01CA249329

Date:	2021 - 2026
Title:	Pro-Drug Enolase Inhibitors in Precision Oncology
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA231509-01

Date:	2020 - 2022
Title:	Imaging the Innate Immune System Predicts Melanoma Immunotherapy Response
Funding Source:	Melanoma Research Foundation
Role:	Mentor

Date:	2020 - 2021
Title:	Fluorescent-guided Surgery in Glioblastoma and Oligodendroglioma
Funding Source:	The University of Texas MD Anderson Cancer Center/NIH
Role:	PI

Date:	2020 - 2025
Title:	Image Guided Cancer Therapy Training Program
Funding Source:	NIH/NCI
Role:	Preceptor
ID:	1T32CA244131-01A1

Date:	2020 - 2025
Title:	Monitoring Therapeutic Intervention in Alcoholic Hepatitis by Multi-modal Imaging
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01AA028880

Date:	2020 - 2024
Title:	A Novel PARP Inhibitor PET Tracer for Breast Cancer
Funding Source:	Department of Defense (DOD)
Role:	Partnering Principal Investigator
ID:	BC190368P1

Date:	2020 - 2025
Title:	Breaking down tumor immune privilege through targeted hypoxia reduction
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	R01CA251816

Date:	2020 - 2025
Title:	Diagnosis and Monitoring of Inflammation and Cell Death in NASH Using PET/CT
Funding Source:	NIH/NIDDK
Role:	Co-PI
ID:	R01DK125518

Date:	2020 - 2023
Title:	Illuminating B7-H3 Protein Dimerization and Function
Funding Source:	NIH/NCI
Role:	Mentor
ID:	F32CA250323

Date:	2020 - 2022
Title:	Directed Evolution of Cyclic Peptides to Enhance Chemotherapeutic Deliver Across the Blood-Brain Barrier
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2020 - 2025
Title:	Targeting Oxidative Phosphorylation to Reduce the Incidence and Therapeutic Resistance of Melanoma Brain Metastasis
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2020 - 2025
Title:	Targeted Inhibition of Autophagy for Treatment of Dormant Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01CA248195

Date:	2020 - 2022
Title:	Multi-modal Imaging for the Prevention of Liver Cancer
Funding Source:	Emerson Collective
Role:	Collaborator

Date:	2020 - 2023
Title:	Reverting Tumor Hypoxia to Maximize Anti-tumor Immunity
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	FP200236

Date:	2020 - 2023
Title:	The Role of Tumor-Targeted TLR5 Activation in Reversing Immune Checkpoint Therapy Resistance
Funding Source:	NIH/NCI
Role:	Mentor
ID:	F30CA239332

Date:	2019 - 2020
Title:	Tumor-associated Neutrophils Limit Immunotherapy in Melanoma
Funding Source:	The University of Texas MD Anderson Cancer Center/NIH
Role:	Mentor

Date:	2019 - 2021
Title:	Myeloid-derived Suppressor Cells Limit lmmunotherapy in Melanoma
Funding Source:	Melanoma Research Foundation
Role:	Mentor
ID:	N/A

Date:	2019 - 2022
Title:	Myeloid-Derived Suppressor Cells Expressing Myeloperoxidase Directly Inhibit Adaptive Immune Cells Limiting Immunotherapy in Melanoma
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Mentor
ID:	W81XWH1910203

Date:	2019 - 2023
Title:	SPORE in Brain Cancer
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	2P50CA127001

Date:	2019 - 2024
Title:	Image Guided Cancer Therapy Training Program
Funding Source:	NIH/NCI
Role:	Preceptor
ID:	1T32CA244131-01

Date:	2019 - 2024
Title:	[18F]FAZA PET/CT for Monitoring Target Engagement of a Novel Complex I Inhibitor
Funding Source:	NIH/NCI
Role:	PI
ID:	R01CA231506

Date:	2019 - 2021
Title:	Directed Evolution of PET Imaging Agents for Her2-positive Brain Metastases
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2019 - 2023
Title:	Imaging PARP1 Activity using a Novel PET Tracer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP190244

Date:	2018 - 2024
Title:	Membrane Permeant Peptides for Imaging Cell Function
Funding Source:	NIH/NCI
Role:	PI
ID:	R01EY019587

Date:	2018 - 2023
Title:	Cancer Center Support Grant
Funding Source:	NIH/NCI
Role:	Co-Program Leader
ID:	P30 CA016672

Date:	2016 - 2021
Title:	MD Anderson Cancer Center Prostate Cancer SPORE – Project 1: Integrating Ipilimumab Immunotherapy with Approved Treatment Strategies in CRPC
Funding Source:	NIH/NCI
Role:	Co-I
ID:	P50 CA140388

Date:	2016 - 2018
Title:	Mechanisms of carcinogenesis and therapeutic vulnerabilities associated with RBM10 loss in KRAS mutant NSCLC
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	W81XWH-15-LCRP-CDA

Date:	2016 - 2019
Title:	Radiomics in Glioblastoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP160150

Date:	2015 - 2021
Title:	Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized Pyruvate
Funding Source:	UT MD Anderson Barbara Cox Anthony Estate
Role:	Principal Investigator-MDACC

Date:	2015 - 2016
Title:	Addressing Critical Unmet Needs in Triple Negative Breast Cancer with Immuno-PET
Funding Source:	UT MD Anderson Cancer Center
Role:	PI
ID:	MDACC Knowledge Gaps

Date:	2015 - 2020
Title:	Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology
Funding Source:	NIH/NCI
Role:	Co-I
ID:	T32-CA196561

Date:	2015 - 2021
Title:	Quantitative Imaging Analysis Core (QIAC) Portal and Analysis Resource
Funding Source:	SU2C/AACR
Role:	PI
ID:	SU2C-AACR-DT17-15

Date:	2015 - 2019
Title:	Employing Mouse Models to Translate Early Detection of Pancreas Cancer
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	R01-CA195733

Date:	2014 - 2016
Title:	STARS Award
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	STARS

Date:	2013 - 2018
Title:	Membrane Permeant Peptides for Imaging Cell Function
Funding Source:	NIH/NCI
Role:	PI
ID:	R01-EY019587

Date:	2013 - 2016
Title:	Novel PET Agent for Myocardial Perfusion Imaging
Funding Source:	U.S. National Institutes of Health
Role:	Investigator
ID:	R01-HL111163

Date:	2013 - 2016
Title:	Imaging Metastasis in Bone Windows In Vivo
Funding Source:	UT MD Anderson Cancer Center
Role:	Mentor
ID:	Odyssey Postdoctoral Research Fellowship

Date:	2013 - 2014
Title:	Characterization of Novel Radiosensitizers Identified in a Bioluminescent Glioblastoma-Stromal Interaction Screen
Funding Source:	Radiation Oncology, RSNA Research Resident Grant
Role:	Co-Mentor
ID:	#RR1306

Date:	2012 - 2017
Title:	WU-MDACC Molecular Imaging Center
Funding Source:	NIH/NCI
Role:	PI
ID:	P50-CA094056

Date:	2012 - 2013
Title:	Development of a Novel Ga-68 PET Myocardial Perfusion Imaging Agent
Funding Source:	Washington University, Bear Cub Fund
Role:	PI

Date:	2012 - 2013
Title:	Tumor-Stromal Interaction as a Potential Target of Radiation Therapy in Glioblastoma
Funding Source:	Radiation Oncology, Holman Research Pathway, American Board of Radiology
Role:	Mentor

Date:	2012 - 2013
Title:	WU Physician-Scientist Training Program, Bioluminescence Imaging of Myeloperoxidase Activity
Funding Source:	NIH Cardiovascular Training Grant
Role:	Mentor
ID:	3040-56869A

Date:	2012 - 2013
Title:	Targeting an RNA Surveillance Pathway in Pediatric Cancer
Funding Source:	Children’s Discovery Institute
Role:	Investigator
ID:	MC-II-2012-215

Date:	2012 - 2014
Title:	21st Century Imaging Sciences: WU Graduate Student Training
Funding Source:	NIH/NIBIB
Role:	PI
ID:	EB014855

Date:	2011 - 2014
Title:	From Breast to Bone: Tracking Gene Expression Changes Responsible for Breast Cancer Metastasis in a Humanized Mouse Model with Molecular Imaging
Funding Source:	DOD (Army) Breast Cancer Research Program Postdoctoral Fellowship Award
Role:	Co-Mentor
ID:	BC103624

Date:	2011 - 2014
Title:	Bioluminescence Imaging of Atherosclerosis-Associated Reactive Oxygen Species
Funding Source:	NIH Pre-Doctoral Fellowship, NHLBI
Role:	Mentor
ID:	F30 HL107009

Date:	2011 - 2014
Title:	p21 (Waf1/Cip1) Regulatory Pathway as a Target for Chemo- and Radio-protection in Advanced Prostate Cancer
Funding Source:	DOD (ARMY) Prostate Cancer Research Program Pre-Doctoral Fellowship
Role:	Co-Mentor
ID:	PC101951

Date:	2010 - 2012
Title:	Graduate Pre-Doctoral Award, Analysis of the NF-kappa B Pathway using Bioluminescence Imaging
Funding Source:	WU Molecular Oncology Training Program
Role:	Mentor
ID:	T32 CA113275

Date:	2010 - 2013
Title:	Bioluminescence Imaging of Mechanisms of Bisphosphonates as Anti-tumor Agents
Funding Source:	U.S. Department of Defense, Idea Expansion Award
Role:	PI
ID:	BC096369

Date:	2010 - 2013
Title:	Enabling Applied Genomic Technologies in Pediatrics
Funding Source:	Children’s Discovery Institute
Role:	Investigator
ID:	CDI-LI-2010-94

Date:	2010 - 2011
Title:	Bioluminescence System to Investigate Inflammation
Funding Source:	Imaging Sciences Pathway Graduate Student Training
Role:	Mentor
ID:	T90 DA022871

Date:	2010 - 2011
Title:	Generation and Analysis of a p21 Luciferase Knock-in Reporter Mouse
Funding Source:	Imaging Sciences Pathway Graduate Student Training
Role:	Mentor
ID:	T90 DA022871

Date:	2010 - 2011
Title:	High Throughput RNA Interference and Pharmaceutical Screens of GABA Metabolism in Prostate Cancer Hypoxia
Funding Source:	Radiology, RSNA Research Resident Grant
Role:	Mentor
ID:	#RR1031

Date:	2010 - 2013
Title:	Targeting the Pre-Metastatic Niche
Funding Source:	National Institutes of Health, Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) Award
Role:	Co-Mentor
ID:	5K12HD001459

Date:	2009 - 2013
Title:	Membrane Permeant Peptides for Imaging Cell Function
Funding Source:	U.S. National Institutes of Health, NEI
Role:	PI
ID:	R01-EY019587

Date:	2009 - 2012
Title:	Caspase Activated Probes For In Vivo Optical Imaging of Retinal Neurodegeneration
Funding Source:	Ruth L. Kirchstein National Research Service Post-Doctoral Fellowship Award, NIH
Role:	Mentor
ID:	F32 EY020051

Date:	2009 - 2012
Title:	Discovery of Synthetic Sick Genes in B-catenin Addicted Colorectal Cancer
Funding Source:	American Cancer Society Post-Doctoral Fellowship Award
Role:	Mentor
ID:	PF-09-266-01-CSM

Date:	2008 - 2009
Title:	Graduate Pre-Doctoral Award, Regulation of the Wnt/beta-catenin Pathway by VEGFR-1
Funding Source:	WU Molecular Oncology Training Program
Role:	Mentor
ID:	T32 CA113275

Date:	2008 - 2009
Title:	Enabling Applied Genomic Technologies in Pediatrics
Funding Source:	Children’s Discovery Institute
Role:	Investigator
ID:	MC-LI-2006-01

Date:	2007 - 2010
Title:	Elucidating Mechanisms of Farnesyltransferase Inhibitor Action and Resistance in Breast Cancer by Bioluminescence Imaging
Funding Source:	U.S. Department of Defense, Synergistic Idea Award
Role:	PI
ID:	BC060037

Date:	2007 - 2008
Title:	Pilot Project Grant, Targeting Mutant p53-Mediated Transactivation of the MDR1 Gene
Funding Source:	American Cancer Society and Washington University Siteman Cancer Center
Role:	Mentor

Date:	2007 - 2012
Title:	WU Molecular Imaging Center
Funding Source:	NIH/NCI
Role:	PI
ID:	P50-CA094056

Date:	2007 - 2010
Title:	Technetium-99m-SPECT Agents for Imaging B-Amyloid in Alzheimer’s Disease
Funding Source:	U.S. National Institutes of Health, NIA
Role:	Investigator
ID:	R21-AG030498

Date:	2006 - 2010
Title:	Targeted Therapy of Glial NF Signaling Pathways
Funding Source:	Department of Defense (DOD)
Role:	Investigator
ID:	W81XWH-06-1-0222

Date:	2005 - 2007
Title:	Targeted Imaging and Therapy of Multidrug Resistance
Funding Source:	U.S. Department of Energy, Molecular Nuclear Medicine Program
Role:	PI
ID:	ER61885

Date:	2004
Title:	Society for Molecular Imaging 3rd Annual Meeting
Funding Source:	NIH/NCI
Role:	PI
ID:	R13 CA112680

Date:	2004
Title:	Modulation of MDR with Tariquidar
Funding Source:	QLT, Inc
Role:	PI

Date:	2004 - 2006
Title:	Graduate Pre-Doctoral Award, “Mechanisms of Regulation of the Wnt/-Catenin Signaling Pathway in Real-Time Using Bioluminescence Imaging
Funding Source:	WU Molecular Oncology Training Program
Role:	Mentor
ID:	T32 CA113275

Date:	2004
Title:	14-3-3 and Breast Cancer
Funding Source:	Washington University Siteman Cancer Center
Role:	Co-PI

Date:	2004 - 2009
Title:	Membrane Permeant Peptides for Imaging Cell Function
Funding Source:	NIH/NCI
Role:	PI
ID:	R01-CA82841

Date:	2002 - 2007
Title:	WU Molecular Imaging Center
Funding Source:	NIH/NCI
Role:	PI
ID:	P50-CA094056

Date:	2001 - 2006
Title:	Targeting Chloroquine Resistance with Fe(III) Complexes
Funding Source:	NIH/NIAID
Role:	Investigator
ID:	AI45640

Date:	2000 - 2005
Title:	Imaging Function and Regulation of Multidrug Resistance
Funding Source:	U.S. Department of Energy, Molecular Nuclear Medicine Program
Role:	PI
ID:	ER61885

Date:	2000 - 2002
Title:	WU Molecular Imaging Center Planning Grant
Funding Source:	NIH/NCI
Role:	PI
ID:	CA86251

Date:	2000 - 2001
Title:	Summer Research Fellowship, Role of MRP4 and MRP5 in Efflux Transport of HSV-1 Thymidine Kinase Substrates
Funding Source:	Howard Hughes Medical Institute
Role:	Mentor

Date:	1999 - 2006
Title:	Imaging Multidrug Resistance and Modulation in Breast Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	R01-CA83059

Date:	1999 - 2000
Title:	Detection of P-glycoprotein-Mediated Multidrug Resistance and Prediction of Response to Chemotherapy in Advanced Breast Cancer
Funding Source:	Washington University Siteman Cancer Center
Role:	Co-PI

Date:	1999 - 2004
Title:	Membrane Permeant Peptides for Imaging Cell Function
Funding Source:	NIH/NCI
Role:	PI
ID:	R01-CA82841

Date:	1999 - 2004
Title:	Research Resource in Radionuclide Research
Funding Source:	NIH/NCI
Role:	Investigator
ID:	PPG RR83059

Date:	1999 - 2000
Title:	Targeting Chloroquine Resistance with Fe(III) Complexes
Funding Source:	NIH/NIAID
Role:	Investigator
ID:	AI45640

Date:	1997 - 1999
Title:	Summer Research Fellowship and Biology Honors Thesis, Characterization of Tc-99m-Tetrofosmin as a Transport Substrate of MDR1 P-glycoprotein
Funding Source:	Howard Hughes Medical Institute
Role:	Mentor

Date:	1997 - 2000
Title:	Targeting Multidrug Resistance with Metal Complexes
Funding Source:	U.S. Department of Energy, Molecular Nuclear Medicine Program
Role:	PI
ID:	ER61885

Date:	1997 - 1999
Title:	MDR Modulation with LY335979
Funding Source:	Eli Lilly and Co., Inc
Role:	PI

Date:	1997 - 2002
Title:	MDR1 P-glycoprotein and Sterol Trafficking
Funding Source:	U.S. National Institutes of Health
Role:	Mentor
ID:	KO8 NHLBI, Mentored Physician-Scientist Award

Date:	1996 - 1998
Title:	Characterization of Tc-99m-N2O2P2 Complexes for Functional Imaging of Multidrug Resistance in Cancer
Funding Source:	Radiological Society of North America (RSNA)
Role:	Mentor

Date:	1996 - 1997
Title:	Characterization of Tc-Q Complexes for Functional Imaging of Multidrug Resistance
Funding Source:	Society of Nuclear Medicine
Role:	Mentor

Date:	1996 - 1999
Title:	Modulation of P-glycoprotein with Metallopharmaceuticals
Funding Source:	NIH/NCI
Role:	PI
ID:	CA65735

Date:	1995 - 1998
Title:	In Vivo Studies for Functional Imaging of Multidrug Resistance
Funding Source:	Mallinckrodt Medical, Inc
Role:	PI

Date:	1994 - 1997
Title:	Targeting Multidrug Resistance with Tc-Isonitrile Complexes
Funding Source:	U.S. Department of Energy, Molecular Nuclear Medicine Program
Role:	PI
ID:	ER61885

Date:	1994 - 1997
Title:	Multidrug Resistance Modulation with GG918
Funding Source:	Glaxo-Wellcome, Inc
Role:	PI

Date:	1994 - 1997
Title:	In Vitro Studies for Functional Imaging of Multidrug Resistance
Funding Source:	Washington University-Mallinckrodt Medical Inc
Role:	PI

Date:	1994 - 1995
Title:	Functional Characterization of Multidrug Resistance P-glycoprotein with Tc-99m-Sestamibi
Funding Source:	Radiological Society of North America (RSNA)
Role:	Mentor

Date:	1993 - 1995
Title:	Multidrug Resistance Modulation
Funding Source:	Vertex Pharmaceuticals
Role:	PI

Date:	1993 - 1994
Title:	Targeting Multidrug Resistance with Tc-Isonitriles
Funding Source:	Milton Fund, Harvard Medical School
Role:	PI

Date:	1993 - 1994
Title:	Imaging Expression of MDR with Tc-99m Labeled Antisense Oligodeoxyribonucleotides
Funding Source:	Society of Nuclear Medicine
Role:	Mentor

Date:	1992 - 1997
Title:	Imaging Membrane Potentials with Tc-Isonitrile Complexes
Funding Source:	American Heart Association Established Investigatorship
Role:	PI
ID:	92-0124

Date:	1991 - 1993
Title:	Cellular Uptake Mechanisms of Mn-DPDP
Funding Source:	Salutar/Nycomed Inc
Role:	PI

Date:	1990 - 1995
Title:	Uptake Mechanisms of Tc Perfusion Agents
Funding Source:	NIH/NHLBI
Role:	PI
ID:	HL42966

Date:	1990 - 1992
Title:	Uptake Mechanisms of Tc-99m-SESTAMIBI
Funding Source:	Dupont, Dupont Pharma Radiopharmaceuticals
Role:	PI

Date:	1989 - 1990
Title:	Monitoring Membrane Potential Noninvasively
Funding Source:	Whitaker Health Science Fund, Harvard Medical School and Massachusetts Institute of Technology
Role:	PI

Date:	1989 - 1991
Title:	Uptake Mechanisms of Tc-99m Based Myocardial
Funding Source:	Radiological Society of North America (RSNA)
Role:	PI

Selected Publications

Peer-Reviewed Articles

Whiting N, Hu J, Pudakalakatti S, McCowan CV, Ramezani S, Davis JS, Millward NZ, Engel BJ, Liu JX, Gellci K, Seo H, Brown D, Enriquez JS, Menter DG, Millward SW, Gammon ST, Piwnica-Worms D, Farach-Carson MC, Carson D, Constantinou PE, Bhattacharya P. Targeted Molecular MRI of Colorectal Cancer by Antibody Functionalized Hyperpolarized Silicon Particles. bioRxiv, 2025. e-Pub 2025. PMID: 40654854.
Millward SW, Wei P, Piwnica-Worms D, Gammon ST. Can the Discovery of High-Impact Diagnostics Be Improved by Matching the Sampling Rate of Clinical Diagnostics to the Frequency Domain of Diagnostic Information?. Cancers (Basel) 17(9), 2025. e-Pub 2025. PMID: 40361314.
Lavery TCM, Rasmussen CA, Katz AW, Kim CBY, Ver Hoeve JN, Miller PE, Sonnentag PJ, Christian BJ, Murphy CJ, Piwnica-Worms DR, Gammon ST, Qiu X, Kaufman PL, Nork TM. Development of Microcystoid Macular Degeneration in the Retina of Nonhuman Primates: Time-Course and Associated Pathologies. Curr Eye Res 50(1):93-100, 2025. e-Pub 2025. PMID: 39290166.
Sutton MN, Glazer SE, Al Zaki A, Napoli A, Yang P, Bhosale P, Liu J, Gammon ST, Piwnica-Worms D. Statins inhibit onco-dimerization of the 4Ig isoform of B7-H3. bioRxiv, 2024. e-Pub 2024. PMID: 39763965.
Liu S, Gammon ST, Tan L, Gao Y, Kim K, Williamson IK, Pham J, Davidian A, Khanna R, Gould BD, Salazar R, Vitrac H, Dinh A, Lien EC, de L Vitorino FN, Gongora JM, Martinez SA, Lawrence CSC, Kransdorf EP, Leffer D, Hanson B, Garcia BA, Vander Heiden MG, Lorenzi PL, Taegtmeyer H, Piwnica-Worms D, Martin JF, Karlstaedt A. ATP-dependent citrate lyase Drives Left Ventricular Dysfunction by Metabolic Remodeling of the Heart. bioRxiv, 2024. e-Pub 2024. PMID: 38948703.
Powell RT, Rinkenbaugh AL, Guo L, Cai S, Shao J, Zhou X, Zhang X, Jeter-Jones S, Fu C, Qi Y, Baameur Hancock F, White JB, Stephan C, Davies PJ, Moulder S, Symmans WF, Chang JT, Piwnica-Worms H. Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer. NPJ Breast Cancer 10(1):37, 2024. e-Pub 2024. PMID: 38802426.
Awad D, Cao PHA, Pulliam TL, Spradlin M, Subramani E, Tellman TV, Ribeiro CF, Muzzioli R, Jewell BE, Pakula H, Ackroyd JJ, Murray MM, Han JJ, Leng M, Jain A, Piyarathna B, Liu J, Song X, Zhang J, Klekers AR, Drake JM, Ittmann MM, Coarfa C, Piwnica-Worms D, Farach-Carson MC, Loda M, Eberlin LS, Frigo DE. Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity. Cancer Res 84(5):703-724, 2024. e-Pub 2024. PMID: 38038968.
Liu A, Gammon ST, Pisaneschi F, Boda A, Ager CR, Piwnica-Worms D, Hong DS, Curran MA. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. JCI Insight 9(1), 2024. e-Pub 2024. PMID: 37988164.
Sutton MN, Glazer SE, Muzzioli R, Yang P, Gammon ST, Piwnica-Worms D. Dimerization of the 4Ig isoform of B7-H3 in tumor cells mediates enhanced proliferation and tumorigenic signaling. Commun Biol 7(1):21, 2024. e-Pub 2024. PMID: 38182652.
Qiu X, Gammon ST, Rasmussen C, Pisaneschi F, Kim CBY, Ver Hoeve J, Millward SW, Barnett EM, Nork TM, Kaufman PL, Piwnica-Worms D. In vivo scanning laser fundus and high-resolution OCT imaging of retinal ganglion cell injury in a non-human primate model with an activatable fluorescent-labeled TAT peptide probe. PLoS One 19(12):e0313579, 2024. e-Pub 2024. PMID: 39642160.
Engel BJ, Paolillo V, Uddin MN, Gonzales KA, McGinnis KM, Sutton MN, Patnana M, Grindel BJ, Gores GJ, Piwnica-Worms D, Beretta L, Pisaneschi F, Gammon ST, Millward SW. Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568603.
Radaram B, Glazer SE, Yang P, Li CW, Hung MC, Gammon ST, Alauddin M, Piwnica-Worms D. Evaluation of 89Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET. ACS Omega 8(19):17181-17194, 2023. e-Pub 2023. PMID: 37214681.
Sun C, Ye Y, Tan Z, Liu Y, Li Y, Hu W, Liang K, Egranov SD, Huang LA, Zhang Z, Zhang Y, Yao J, Nguyen TK, Zhao Z, Wu A, Marks JR, Caudle AS, Sahin AA, Gao J, Gammon ST, Piwnica-Worms D, Hu J, Chiao PJ, Yu D, Hung MC, Curran MA, Calin GA, Ying H, Han L, Lin C, Yang L. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Sci Adv 9(5):eadd6995, 2023. e-Pub 2023. PMID: 36724291.
Liu TW, Gammon ST, Yang P, Ma W, Wang J, Piwnica-Worms D. Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma. J Immunother Cancer 11(2), 2023. e-Pub 2023. PMID: 36805920.
Gonzalez C, Williamson S, Gammon ST, Glazer S, Rhee JH, Piwnica-Worms D. TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy. Commun Biol 6(1):31, 2023. e-Pub 2023. PMID: 36635337.
McIntosh LA, Burns JD, Tereshatov EE, Muzzioli R, Hagel K, Jinadu NA, McCann LA, Picayo GA, Pisaneschi F, Piwnica-Worms D, Schultz SJ, Tabacaru GC, Abbott A, Green B, Hankins T, Hannaman A, Harvey B, Lofton K, Rider R, Sorensen M, Tabacaru A, Tobin Z, Yennello SJ. Production, isolation, and shipment of clinically relevant quantities of astatine-211: A simple and efficient approach to increasing supply. Nucl Med Biol 126-127:108387, 2023. e-Pub 2023. PMID: 37837782.
Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 610(7932):E15-E17, 2022. e-Pub 2022. PMID: 36198804.
Qiu X, Gammon ST, Johnson JR, Pisaneschi F, Millward SW, Barnett EM, Piwnica-Worms D. Apoptosis Detection in Retinal Ganglion Cells Using Quantitative Changes in Multichannel Fluorescence Colocalization. Biosensors (Basel) 12(9), 2022. e-Pub 2022. PMID: 36140078.
Kerk SA, Lin L, Myers AL, Sutton DJ, Andren A, Sajjakulnukit P, Zhang L, Zhang Y, Jiménez JA, Nelson BS, Chen B, Robinson A, Thurston G, Kemp SB, Steele NG, Hoffman MT, Wen HJ, Long D, Ackenhusen SE, Ramos J, Gao X, Nwosu ZC, Galban S, Halbrook CJ, Lombard DB, Piwnica-Worms DR, Ying H, Pasca di Magliano M, Crawford HC, Shah YM, Lyssiotis CA. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Elife 11, 2022. e-Pub 2022. PMID: 35815941.
Pollard AC, Paolillo V, Radaram B, Qureshy S, Li L, Maity T, Wang L, Uddin MN, Wood CG, Karam JA, Pagel MD, Piwnica-Worms D, Millward SW, Fowlkes NW, Norton W, Engel BJ, Pisaneschi F, Zacharias NM. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[18F]Fluoroglutamine. Mol Imaging Biol. e-Pub 2022. PMID: 35732988.
Pisaneschi F, Gammon ST, Paolillo V, Qureshy SA, Piwnica-Worms D. Imaging of innate immunity activation in vivo with a redox-tuned PET reporter. Nat Biotechnol. e-Pub 2022. PMID: 35190688.
Sutton MN, Gammon ST, Muzzioli R, Pisaneschi F, Radaram B, Yang P, Piwnica-Worms D. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging. Mol Imaging Biol. e-Pub 2021. PMID: 34905147.
Salzillo TC, Mawoneke V, Weygand J, Shetty A, Gumin J, Zacharias NM, Gammon ST, Piwnica-Worms D, Fuller GN, Logothetis CJ, Lang FF, Bhattacharya PK. Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance. Cells 10(10), 2021. e-Pub 2021. PMID: 34685601.
Rao Y, Gammon S, Sutton MN, Zacharias NM, Bhattacharya P, Piwnica-Worms D. Excess Exogenous Pyruvate Inhibits Lactate Dehydrogenase Activity in Live Cells in a MCT1-Dependent Manner. J Biol Chem:100775. e-Pub 2021. PMID: 34022218.
Iommelli F, De Rosa V, Terlizzi C, Fonti R, Camerlingo R, Stoppelli MP, Stewart CA, Byers LA, Piwnica-Worms D, Del Vecchio S. A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33922104.
Liu TW, Gammon ST, Yang P, Fuentes D, Piwnica-Worms D. Myeloid cell-derived HOCl is a paracrine effector that trans-inhibits IKK/NF-κB in melanoma cells and limits early tumor progression. Sci Signal 14(677), 2021. e-Pub 2021. PMID: 33824181.
Liu TW, Gammon ST, Piwnica-Worms D. Multi-Modal Multi-Spectral Intravital Microscopic Imaging of Signaling Dynamics in Real-Time during Tumor-ImmuneInteractions. Cells 10(3), 2021. e-Pub 2021. PMID: 33652682.
Liu TW, Gammon ST, Fuentes D, Piwnica-Worms D. Multi-Modal Multi-Spectral Intravital Macroscopic Imaging of Signaling Dynamics in Real Time during Tumor-Immune Interactions. Cells 10(3), 2021. e-Pub 2021. PMID: 33668735.
Gray JP, Uddin MN, Chaudhari R, Sutton MN, Yang H, Rask P, Locke H, Engel BJ, Batistatou N, Wang J, Grindel BJ, Bhattacharya P, Gammon ST, Zhang S, Piwnica-Worms D, Kritzer JA, Lu Z, Bast RC, Millward SW. Directed evolution of cyclic peptides for inhibition of autophagy. Chem Sci 12(10):3526-3543, 2021. e-Pub 2021. PMID: 34163626.
Gammon ST, Engel BJ, Gores GJ, Cressman E, Piwnica-Worms D, Millward SW. Mistiming Death: Modeling the Time-Domain Variability of Tumor Apoptosis and Implications for Molecular Imaging of Cell Death. Mol Imaging Biol, 2020. e-Pub 2020. PMID: 32519246.
Rao Y, Gammon S, Zacharias NM, Liu T, Salzillo T, Xi Y, Wang J, Bhattacharya P, Piwnica-Worms D. Hyperpolarized [1-13C]pyruvate-to-[1-13C]lactate conversion is rate-limited by monocarboxylate transporter-1 in the plasma membrane. Proc Natl Acad Sci U S A 117(36):22378-22389, 2020. e-Pub 2020. PMID: 32839325.
Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother 69(8):1519-1534, 2020. e-Pub 2020. PMID: 32300858.
Rao SH, Virarkar M, Yang WT, Carter BW, Liu TA, Piwnica-Worms D, Bhosale PR. Streamlining the Quantitative Metrics Workflow at a Comprehensive Cancer Center. Acad Radiol, 2020. e-Pub 2020. PMID: 32709584.
Li YC, Lytle NK, Gammon ST, Wang L, Hayes TK, Sutton MN, Bast RC, Der CJ, Piwnica-Worms D, McCormick F, Wahl GM. Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. Proc Natl Acad Sci U S A 117(22):12121-12130, 2020. e-Pub 2020. PMID: 32424096.
Le Roux LG, Qiu X, Jacobsen MC, Pagel MD, Gammon ST, Piwnica-Worms DR, Schellingerhout D. Axonal Transport as an In Vivo Biomarker for Retinal Neuropathy. Cells 9(5), 2020. e-Pub 2020. PMID: 32456061.
Dutta P, Pando SC, Mascaro M, Riquelme E, Zoltan M, Zacharias NM, Gammon ST, Piwnica-Worms D, Pagel MD, Sen S, Maitra A, Shams S, McAllister F, Bhattacharya PK. Early Detection of Pancreatic Intraepithelial Neoplasias (PanINs) in Transgenic Mouse Model by Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy. Int J Mol Sci 21(10), 2020. e-Pub 2020. PMID: 32466260.
Cao Q, Wang W, Zhou M, Huang Q, Wen X, Zhao J, Shi S, Geng K, Li F, Hatakeyama H, Xu C, Piwnica-Worms D, Peng W, Zhou D, Sood AK, Li C. Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition. Nanomedicine 25:102169, 2020. e-Pub 2020. PMID: 32059873.
Vashisht Gopal YN, Gammon S, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clin Cancer Res 25(21):6429-6442, 2019. e-Pub 2019. PMID: 31439581.
Gammon ST, Pisaneschi F, Bandi ML, Smith MG, Sun Y, Rao Y, Muller F, Wong F, De Groot J, Ackroyd J, Mawlawi O, Davies MA, Gopal YNV, Di Francesco ME, Marszalek JR, Dewhirst M, Piwnica-Worms D. Mechanism-specific pharmacodynamics of a novel complex-I inhibitor quantified by imaging reversal of consumptive hypoxia with [18F]FAZA PET in vivo. Cells 8:1487, 2019. e-Pub 2019. PMID: 31766580.
Radaram B, Pisaneschi F, Rao Y, Yang P, Piwnica-Worms D, Alauddin MM. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and prelimary biological studies of flouoroethyl analogues of crizotinib, alectinib, and certinib. Eur J Med Chem 182, 2019. e-Pub 2019. PMID: 31425908.
Zacharias NM, Baran N, Shanmugavelandy SS, Lee J, Velez Lujan J, Dutta P, Millward SW, Cai T, Wood CG, Piwnica-Worms D, Konopleva M, Bhattacharya PK. Assessing metabolic intervention with a glutaminase inhibitor in real-time by hyperpolarized magnetic resonance in acute myeloid leukemia. Mol Cancer Ther. e-Pub 2019. PMID: 31387889.
Dutta P, Perez MR, Lee J, Kang Y, Pratt M, Salzillo TC, Weygand J, Zacharias NM, Gammon ST, Koay EJ, Kim M, McAllister F, Sen S, Maitra A, Piwnica-Worms D, Fleming JB, Bhattacharya PK. Combining hyperpolarized real-time metabolic imaging and NMR spectroscopy to identify metabolic biomarkers in pancreatic cancer. J Proteome Res 18(7):2826-2834, 2019. e-Pub 2019. PMID: 31120258.
Biagiotti G, Pisaneschi F, Gammon ST, Machetti F, Ligi MC, Giambastiani G, Tuci G, Powell E, Piwnica-Worms H, Pranzini E, Paoli P, Cicchi S, Piwnica-Worms D. Multiwalled carbon nanotubes for combination therapy: a biodistribution and efficacy pilot study. J Mater Chem B 7(16):2678-2687, 2019. e-Pub 2019. PMID: 31073405.
Orteca G, Pisaneschi F, Rubagotti S, Liu TW, Biagiotti G, Piwnica-Worms D, Iori M, Capponi PC, Ferrari E, Asti M. Development of a potential gallium-68 labelled radiotracer based on DOTA-curcumin for colon-rectal carcinoma: from synthesis to in vivo studies. Molecules 24(3), 2019. e-Pub 2019. PMID: 30759785.
Zacharias N, Lee J, Ramachandran S, Shanmugavelandy S, McHenry J, Dutta P, Millward S, Gammon S, Efstathiou E, Troncoso P, Frigo DE, Piwnica-Worms D, Logothetis CJ, Maity SN, Titus MA, Bhattacharya P. Androgen receptor signaling in castration-resistant prostate cancer alters hyperpolarized pyruvate to lactate conversion and lactate levels in vivo. Mol Imaging Biol 21(2):86-94, 2019. e-Pub 2019. PMID: 29748904.
Engel BJ, Gammon ST, Chaudhari R, Lu Z, Pisaneschi F, Yang H, Ornelas A, Yan V, Kelderhouse L, Najjar A, Tong WP, Zhang S, Piwnica-Worms D, Bast Jr RC, Millward SW. Caspase-3 substrates for non-invasive pharmacodynamic imaging of apoptosis by PET/CT. Bioconjug Chem 29(9):3180-3195, 2018. e-Pub 2018. PMID: 30168713.
Ku G, Huang Q, Wen X, Ye J, Piwnica-Worms D, Li C. Spatial and Temporal Confined Photothermolysis of Cancer Cells Mediated by Hollow Gold Nanospheres Targeted to Epidermal Growth Factor Receptors. ACS Omega 3(5):5888-5895, 2018. e-Pub 2018. PMID: 29876540.
Zhao J, Wang H, Hsiao CH, Chow DS, Koay EJ, Kang Y, Wen X, Huang Q, Ma Y, Bankson JA, Ullrich SE, Overwijk W, Maitra A, Piwnica-Worms D, Fleming JB, Li C. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials 159:215-228, 2018. e-Pub 2018. PMID: 29331808.
Zinn PO, Singh SK, Kotrotsou A, Hassan I, Thomas G, Luedi MM, Elakkad A, Elshafeey N, Idris T, Mosley J, Gumin J, Fuller GN, deGroot JF, Baladandayuthapani V, Sulman EP, Kumar AJ, Sawaya R, Lang FF, Piwnica-Worms D, Colen RR. A co-clinical radiogenomic validation study - Conserved magnetic resonance radiomic appearance of Periostin expressing Glioblastoma in patients and xenograft models. Clin Cancer Res 24(24):6288-6299, 2018. e-Pub 2018. PMID: 30054278.
Ku G, Huang Q, Wen X, Ye J, Piwnica-Worms D, Li C. Spatial and temporal confined photothermolysis of cancer cells mediated by hollow gold nanospheres targeted to epidermal growth factor receptors. ACS Omega 3(5):5888-5895, 2018. e-Pub 2018.
Flentie K, Gonzalez C, Kocher B, Wang Y, Zhu H, Marasa J, Piwnica-Worms D. Nucleoside diphosphate kinase-3 (NME3) enhances TLR5-induced NFκB activation. Mol Cancer Res 16(6):986-999, 2018. e-Pub 2018. PMID: 29523766.
Nickless A, Cheruiyot A, Flanagan KC, Piwnica-Worms D, Stewart SA, You Z. p38 MAPK inhibits nonsense-mediated RNA decay in response to persistent DNA damage in noncycling cells. J Biol Chem 292(37):15266-15276, 2017. e-Pub 2017. PMID: 28765281.
Pisaneschi F, Kelderhouse LE, Hardy A, Engel BJ, Mukhopadhyay U, Gonzalez-Lepera C, Gray JP, Ornelas A, Takahashi TT, Roberts RW, Fiacco SV, Piwnica-Worms D, Millward SW. Automated resin-based method to enhance the specific activity of fluorine-18 clicked PET radiotracers. Bioconjug Chem 28(2):583-589, 2017. e-Pub 2017. PMID: 28150941.
Perera S, Piwnica-Worms D, Alauddin MM. Synthesis of a [(18) F]-labeled ceritinib analogue for positron emission tomography of anaplastic lymphoma kinase, a receptor tyrosine kinase, in lung cancer. J Labelled Comp Radiopharm 59(3):103-8, 2016. e-Pub 2016. PMID: 26853088.
Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms DR, Cashen AF, Bartlett NL, Wong HC, Fehniger TA. The IL-15-based ALT-803 complex enhances FcγRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clin Cancer Res 22(3):596-608, 2016. e-Pub 2016. PMID: 26423796.
Powell E, Shao J, Yuan Y, Chen HC, Cai S, Echeverria GV, Mistry N, Decker KF, Schlosberg C, Do KA, Edwards JR, Liang H, Piwnica-Worms D, Piwnica-Worms H. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. Breast Cancer Res 18(1):13, 2016. e-Pub 2016. PMID: 26818199.
Tinkum KL, Stemler KM, White LS, Loza AJ, Jeter-Jones S, Michalski BM, Kuzmicki CE, Pless R, Stappenbeck TS, Piwnica-Worms D, Piwnica-Worms H. Fasting protects mice from lethal DNA damage by promoting small intestinal epithelial stem cell survival. Proc Nat'l Acad Science USA 112(51):E7148-7154. e-Pub 2015. PMID: 26644583.
Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523(7559):177-182, 2015. e-Pub 2015. PMID: 26106858.
Sengupta R, Barone A, Marasa J, Taylor S, Jackson E, Warrington NM, Rao S, Kim AH, Leonard JR, Piwnica-Worms D, Rubin JB. Novel chemical library screen identifies naturally occurring plant products that specifically disrupt glioblastoma-endothelial cell interactions. Oncotarget 6(21):18282-18292. e-Pub 2015. PMID: 26286961.
Eissenberg LG, Rettig MP, Ritchey JK, Prior JL, Schwarz SW, Frye J, White BS, Fulton RS, Ghobadi, A, Couriel DR, Seegulam ME, Piwnica-Worms D, Dehdashti F, Cornetta K, DiPersio JF. [18F]FHBG PET/CT imaging of CD34-TK75 transduced donor T cells in relapsed allogeneic stem cell transplant patients: safety and feasibility. Mol Therapy 23(6):1110-1122, 2015. e-Pub 2015. PMID: 25807290.
Kocher BA, White LS, Piwnica-Worms D. DAPK3 suppresses acini morphogenesis and is required for mouse development. Mol Cancer Res 13(2):358-67, 2015. e-Pub 2015. PMID: 25304685.
Sun L, Miyoshi H, Origanti S, Nice TJ, Barger AC, Manieri NA, Fogel LA, French AR, Piwnica-Worms D, Piwnica-Worms H, Virgin HW, Lenschow DJ, Stappenbeck TS. Type I interferons link viral infection to enhanced epithelial turnover and repair. Cell Host Microbe 17(1):85-97, 2015. e-Pub 2015. PMID: 25482432.
Goiffon RJ, Martinez SC, Piwnica-Worms D. A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma. Nat Commun 6:6271, 2015. e-Pub 2015. PMID: 25666092.
Eissenberg LG, Retting M, Dehdashti F, Piwnica-Worms D, DiPersio J. Suicide genes: monitoring cells in patients with a safety switch. Frontiers Pharmacol 5. e-Pub 2014.
Lee Y, Zacharias NM, Piwnica-Worms D, Bhattacharya PK. Chemical reaction-induced multi-molecular polarization (CRIMP). Chem Commun (Camb) 50(86):13030-3, 2014. e-Pub 2014. PMID: 25224323.
Barone A, Sengupta R, Warrington NM, Smith E, Wen PY, Brekken RA, Romagnoli B, Douglas G, Chevalier E, Bauer MP, Dembowsky K, Piwnica-Worms D, Rubin JB. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. Oncotarget 5(20):9811-22, 2014. e-Pub 2014. PMID: 25238146.
Nickless A, Jackson E, Marasa J, Nugent P, Mercer RW, Piwnica-Worms D, You Z. Intracellular calcium regulates nonsense-mediated mRNA decay. Nat Med 20(8):961-6, 2014. e-Pub 2014. PMID: 25064126.
Elhammali A, Ippolito JE, Collins L, Crowley J, Marasa J, Piwnica-Worms D. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov 4(7):828-39, 2014. e-Pub 2014. PMID: 24740997.
Hensley H, Devarajan K, Johnson JR, Piwnica-Worms D, Godwin AK, von Mehren M, Rink L. Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging. Cancer Biol Ther 15(7):911-8, 2014. e-Pub 2014. PMID: 24755645.
Alspach E, Flanagan KC, Luo X, Ruhland MK, Huang H, Pazolli E, Donlin MJ, Marsh T, Piwnica-Worms D, Monahan J, Novack DV, McAllister SS, Stewart SA. p38MAPK plays a crucial role in stromal-mediated tumorigenesis. Cancer Discov 4(6):716-29, 2014. e-Pub 2014. PMID: 24670723.
Liu H, Westergard TD, Cashen A, Piwnica-Worms D, Kunkle L, Vij R, Pham CG, DiPersio J, Cheng EH, Hsieh JJ. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. Cancer Cell 25(4):530-42, 2014. e-Pub 2014. PMID: 24735925.
Garg G, Gibbs J, Belt B, Powell MA, Mutch DG, Goedegebuure P, Collins L, Piwnica-Worms D, Hawkins WG, Spitzer D. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. BMC Cancer 14(1):35, 2014. e-Pub 2014. PMID: 24447304.
Ippolito JE, Piwnica-Worms D. A fluorescence-coupled assay for gamma aminobutyric acid (GABA) reveals metabolic stress-induced modulation of GABA content in neuroendocrine cancer. PLoS One 9(2):e88667, 2014. e-Pub 2014. PMID: 24551133.
Sharma V, Sivapackiam J, Harpstrite SE, Prior JL, Gu H, Rath NP, Piwnica-Worms D. A generator-produced Gallium-68 radiopharmaceutical for PET imaging of myocardial perfusion. PLoS One 9(10):e109361, 2014. e-Pub 2014. PMID: 25353349.
Eissenberg LG, Rettig M, Dehdashti F, Piwnica-Worms D, DiPersio JF. Suicide genes: monitoring cells in patients with a safety switch. Front Pharmacol 5:241, 2014. e-Pub 2014. PMID: 25414668.
Brooks MD, Jackson E, Warrington NM, Luo J, Forys JT, Taylor S, Mao DD, Leonard JR, Kim AH, Piwnica-Worms D, Mitra RD, Rubin JB. PDE7B is a novel, prognostically significant mediator of glioblastoma growth whose expression is regulated by endothelial cells. PLoS One 9(9):e107397, 2014. e-Pub 2014. PMID: 25203500.
Qiu X, Johnson JR, Wilson BS, Gammon ST, Piwnica-Worms D, Barnett EM. Single-cell resolution imaging of retinal ganglion cell apoptosis in vivo using a cell-penetrating caspase-activatable peptide probe. PLoS One 9(2):e88855, 2014. e-Pub 2014. PMID: 24586415.
Garg G, Vangveravong S, Zeng C, Collins L, Hornick M, Hashim Y, Piwnica-Worms D, Powell MA, Mutch DG, Mach RH, Hawkins WG, Spitzer D. Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. Mol Cancer 13:50, 2014. e-Pub 2014. PMID: 24602489.
Macdonald-Obermann JL, Adak S, Landgraf R, Piwnica-Worms D, Pike LJ. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. J Biol Chem 288(42):30773-84, 2013. e-Pub 2013. PMID: 24014028.
Tinkum KL, White LS, Marpegan L, Herzog E, Piwnica-Worms D, Piwnica-Worms H. Forkhead Box O1 (FOXO1), but not p53, contributes to robust induction of p21 expression in fasted mice. J Biol Chem 288(39):27999-8008, 2013. e-Pub 2013. PMID: 23918930.
Sai KK, Huang C, Yuan L, Zhou D, Piwnica-Worms D, Garbow JR, Engelbach JA, Mach RH, Rich KM, McConathy J. 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas. J Nucl Med 54(7):1120-6, 2013. e-Pub 2013. PMID: 23650628.
Liu Z, Chen S, Boyle S, Zhu Y, Zhang A, Piwnica-Worms DR, Ilagan MX, Kopan R. The extracellular domain of Notch2 increases its cell-surface abundance and ligand responsiveness during kidney development. Dev Cell 25(6):585-98, 2013. e-Pub 2013. PMID: 23806616.
Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW, Keely PJ, Longmore GD. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat Cell Biol 15(6):677-87, 2013. e-Pub 2013. PMID: 23644467.
Kocher B, Piwnica-Worms D. Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo. Cancer Discov 3(6):616-29, 2013. e-Pub 2013. PMID: 23585416.
Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 27(2):430-40, 2013. e-Pub 2013. PMID: 22763387.
Yang C, Davis JL, Zeng R, Vora P, Su X, Collins LI, Vangveravong S, Mach RH, Piwnica-Worms D, Weilbaecher KN, Faccio R, Novack DV. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discov 3(2):212-23, 2013. e-Pub 2013. PMID: 23269702.
Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 73(3):1128-41, 2013. e-Pub 2013. PMID: 23221383.
Pong WW, Walker J, Wylie T, Magrini V, Luo J, Emnett RJ, Choi J, Cooper ML, Griffith M, Griffith OL, Rubin JB, Fuller GN, Piwnica-Worms D, Feng X, Hambardzumyan D, DiPersio JF, Mardis ER, Gutmann DH. F11R is a novel monocyte prognostic biomarker for malignant glioma. PLoS One 8(10):e77571, 2013. e-Pub 2013. PMID: 24147027.
Choi J, Ziga ED, Ritchey J, Collins L, Prior JL, Cooper ML, Piwnica-Worms D, DiPersio JF. IFNγR signaling mediates alloreactive T-cell trafficking and GVHD. Blood 120(19):4093-103, 2012. e-Pub 2012. PMID: 22972985.
Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest 122(10):3579-92, 2012. e-Pub 2012. PMID: 22996695.
Johnson JR, Kocher B, Barnett EM, Marasa J, Piwnica-Worms D. Caspase-activated cell-penetrating peptides reveal temporal coupling between endosomal release and apoptosis in an RGC-5 cell model. Bioconjug Chem 23(9):1783-93, 2012. e-Pub 2012. PMID: 22900707.
Li Y, Macdonald-Obermann J, Westfall C, Piwnica-Worms D, Pike LJ. Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization. J Biol Chem 287(37):31116-25, 2012. e-Pub 2012. PMID: 22822073.
Moss BL, Elhammali A, Fowlkes T, Gross S, Vinjamoori A, Contag CH, Piwnica-Worms D. Interrogation of inhibitor of nuclear factor κB α/nuclear factor κB (IκBα/NF-κB) negative feedback loop dynamics: from single cells to live animals in vivo. J Biol Chem 287(37):31359-70, 2012. e-Pub 2012. PMID: 22807442.
Chinault SL, Prior JL, Kaltenbronn KM, Penly A, Weilbaecher KN, Piwnica-Worms D, Blumer KJ. Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter. Clin Cancer Res 18(15):4136-44, 2012. e-Pub 2012. PMID: 22693355.
Flentie K, Kocher B, Gammon ST, Novack DV, McKinney JS, Piwnica-Worms D. A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in Salmonella for conditional bacterial-based tumor therapy. Cancer Discov 2(7):624-37, 2012. e-Pub 2012. PMID: 22728436.
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403):353-60, 2012. e-Pub 2012. PMID: 22722193.
Xu Z, Joshi N, Agarwal A, Dahiya S, Bittner P, Smith E, Taylor S, Piwnica-Worms D, Weber J, Leonard JR. Knocking down nucleolin expression in gliomas inhibits tumor growth and induces cell cycle arrest. J Neurooncol 108(1):59-67, 2012. e-Pub 2012. PMID: 22382782.
Pazolli E, Alspach E, Milczarek A, Prior J, Piwnica-Worms D, Stewart SA. Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression. Cancer Res 72(9):2251-61, 2012. e-Pub 2012. PMID: 22422937.
Blasberg R, Piwnica-Worms D. Imaging: strategies, controversies, and opportunities. Clin Cancer Res 18(3):631-7, 2012. e-Pub 2012. PMID: 22298896.
Chen DY, Lee Y, Van Tine BA, Searleman AC, Westergard TD, Liu H, Tu HC, Takeda S, Dong Y, Piwnica-Worms DR, Oh KJ, Korsmeyer SJ, Hermone A, Gussio R, Shoemaker RH, Cheng EH, Hsieh JJ. A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res 72(3):736-46, 2012. e-Pub 2012. PMID: 22166309.
Fuentealba RA, Marasa J, Diamond MI, Piwnica-Worms D, Weihl CC. An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum Mol Genet 21(3):664-80, 2012. e-Pub 2012. PMID: 22052286.
Heller E, Hurchla MA, Xiang J, Su X, Chen S, Schneider J, Joeng KS, Vidal M, Goldberg L, Deng H, Hornick MC, Prior JL, Piwnica-Worms D, Long F, Cagan R, Weilbaecher KN. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res 72(4):897-907, 2012. e-Pub 2012. PMID: 22186138.
Macdonald-Obermann JL, Piwnica-Worms D, Pike LJ. Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging. Proc Natl Acad Sci U S A 109(1):137-42, 2012. e-Pub 2012. PMID: 22190492.
Woerner BM, Luo J, Brown KR, Jackson E, Dahiya SM, Mischel P, Benovic JL, Piwnica-Worms D, Rubin JB. Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth. Mol Cancer Res 10(1):156-66, 2012. e-Pub 2012. PMID: 22086906.
Rao S, Sengupta R, Choe EJ, Woerner BM, Jackson E, Sun T, Leonard J, Piwnica-Worms D, Rubin JB. CXCL12 mediates trophic interactions between endothelial and tumor cells in glioblastoma. PLoS One 7(3):e33005, 2012. e-Pub 2012. PMID: 22427929.
Dothager RS, Piwnica-Worms D. Nano in cancer: linking chemistry, biology, and clinical applications in vivo. Cancer Res 71(17):5611-5, 2011. e-Pub 2011. PMID: 21862634.
Tinkum KL, Marpegan L, White LS, Sun J, Herzog ED, Piwnica-Worms D, Piwnica-Worms H. Bioluminescence imaging captures the expression and dynamics of endogenous p21 promoter activity in living mice and intact cells. Mol Cell Biol 31(18):3759-72, 2011. e-Pub 2011. PMID: 21791610.
Zhang K, Kim S, Cremasco V, Hirbe AC, Collins L, Piwnica-Worms D, Novack DV, Weilbaecher K, Faccio R. CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Res 71(14):4799-808, 2011. e-Pub 2011. PMID: 21602433.
Smith BA, Daschbach MM, Gammon ST, Xiao S, Chapman SE, Hudson C, Suckow M, Piwnica-Worms D, Gokel GW, Leevy WM. In vivo cell death mediated by synthetic ion channels. Chem Commun (Camb) 47(28):7977-9, 2011. e-Pub 2011. PMID: 21681307.
Wang YV, Leblanc M, Fox N, Mao JH, Tinkum KL, Krummel K, Engle D, Piwnica-Worms D, Piwnica-Worms H, Balmain A, Kaushansky K, Wahl GM. Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. Genes Dev 25(13):1426-38, 2011. e-Pub 2011. PMID: 21724834.
Smith BA, Gammon ST, Xiao S, Wang W, Chapman S, McDermott R, Suckow MA, Johnson JR, Piwnica-Worms D, Gokel GW, Smith BD, Leevy WM. In vivo optical imaging of acute cell death using a near-infrared fluorescent zinc-dipicolylamine probe. Mol Pharm 8(2):583-90, 2011. e-Pub 2011. PMID: 21323375.
Liu Z, Turkoz A, Jackson EN, Corbo JC, Engelbach JA, Garbow JR, Piwnica-Worms DR, Kopan R. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest 121(2):800-8, 2011. e-Pub 2011. PMID: 21266774.
Olanich ME, Moss BL, Piwnica-Worms D, Townsend RR, Weber JD. Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation. Oncogene 30(1):77-86, 2011. e-Pub 2011. PMID: 20802533.
Johnson JR, Piwnica-Worms D. Standing out in the crowd: signal-to-background in molecular imaging. Aust J Chem 64:590-2, 2011. e-Pub 2011.
Pasieka TJ, Collins L, O'Connor MA, Chen Y, Parker ZM, Berwin BL, Piwnica-Worms DR, Leib DA. Bioluminescent imaging reveals divergent viral pathogenesis in two strains of Stat1-deficient mice, and in αßγ interferon receptor-deficient mice. PLoS One 6(9):e24018, 2011. e-Pub 2011. PMID: 21915277.
Ilagan MX, Lim S, Fulbright M, Piwnica-Worms D, Kopan R. Real-time imaging of notch activation with a luciferase complementation-based reporter. Sci Signal 4(181):rs7, 2011. e-Pub 2011. PMID: 21775282.
Zhou P, Gross S, Liu JH, Yu BY, Feng LL, Nolta J, Sharma V, Piwnica-Worms D, Qiu SX. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. FASEB J 24(12):4722-32, 2010. e-Pub 2010. PMID: 20696856.
Lennerz JK, Hurov JB, White LS, Lewandowski KT, Prior JL, Planer GJ, Gereau RW, Piwnica-Worms D, Schmidt RE, Piwnica-Worms H. Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis. Mol Cell Biol 30(21):5043-56, 2010. e-Pub 2010. PMID: 20733003.
Pan MH, Lin J, Prior JL, Piwnica-Worms D. Monitoring molecular-specific pharmacodynamics of rapamycin in vivo with inducible Gal4->Fluc transgenic reporter mice. Mol Cancer Ther 9(10):2752-60, 2010. e-Pub 2010. PMID: 20858726.
Villalobos V, Naik S, Bruinsma M, Dothager RS, Pan MH, Samrakandi M, Moss B, Elhammali A, Piwnica-Worms D. Dual-color click beetle luciferase heteroprotein fragment complementation assays. Chem Biol 17(9):1018-29, 2010. e-Pub 2010. PMID: 20851351.
Sun T, Gianino SM, Jackson E, Piwnica-Worms D, Gutmann DH, Rubin JB. CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. J Neuroimmunol 224(1-2):108-13, 2010. e-Pub 2010. PMID: 20554030.
Warrington NM, Gianino SM, Jackson E, Goldhoff P, Garbow JR, Piwnica-Worms D, Gutmann DH, Rubin JB. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res 70(14):5717-27, 2010. e-Pub 2010. PMID: 20551058.
Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, DiPersio JF. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 116(1):129-39, 2010. e-Pub 2010. PMID: 20424188.
Yang KS, Macdonald-Obermann JL, Piwnica-Worms D, Pike LJ. Asp-960/Glu-961 controls the movement of the C-terminal tail of the epidermal growth factor receptor to regulate asymmetric dimer formation. J Biol Chem 285(31):24014-22, 2010. e-Pub 2010. PMID: 20507979.
Vikis HG, Jackson EN, Krupnick AS, Franklin A, Gelman AE, Chen Q, Piwnica-Worms D, You M. Strain-specific susceptibility for pulmonary metastasis of sarcoma 180 cells in inbred mice. Cancer Res 70(12):4859-67, 2010. e-Pub 2010. PMID: 20501835.
Morgan EA, Schneider JG, Baroni TE, Uluçkan O, Heller E, Hurchla MA, Deng H, Floyd D, Berdy A, Prior JL, Piwnica-Worms D, Teitelbaum SL, Ross FP, Weilbaecher KN. Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit. FASEB J 24(4):1117-27, 2010. e-Pub 2010. PMID: 19933310.
Liu CC, Prior J, Piwnica-Worms D, Bu G. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci U S A 107(11):5136-41, 2010. e-Pub 2010. PMID: 20194742.
Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG, Reilly KM, Piwnica-Worms DR, Gutmann DH. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res 70(4):1356-66, 2010. e-Pub 2010. PMID: 20124472.
Dothager RS, Goiffon RJ, Jackson E, Harpstrite S, Piwnica-Worms D. Cerenkov radiation energy transfer (CRET) imaging: a novel method for optical imaging of PET isotopes in biological systems. PLoS One 5(10):e13300, 2010. e-Pub 2010. PMID: 20949021.
Sondergaard CS, Hess DA, Maxwell DJ, Weinheimer C, Rosová I, Creer MH, Piwnica-Worms D, Kovacs A, Pedersen L, Nolta JA. Human cord blood progenitors with high aldehyde dehydrogenase activity improve vascular density in a model of acute myocardial infarction. J Transl Med 8:24, 2010. e-Pub 2010. PMID: 20214792.
Rauch DA, Hurchla MA, Harding JC, Deng H, Shea LK, Eagleton MC, Niewiesk S, Lairmore MD, Piwnica-Worms D, Rosol TJ, Weber JD, Ratner L, Weilbaecher KN. The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice. PLoS One 5(12):e15755, 2010. e-Pub 2010. PMID: 21209895.
Naik S, Dothager RS, Marasa J, Lewis CL, Piwnica-Worms D. Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer. Clin Cancer Res 15(24):7529-7537. (Cover and Editorial Commentary), 2009. e-Pub 2009. PMID: 20008853.
Ju JS, Fuentealba RA, Miller SE, Jackson E, Piwnica-Worms D, Baloh RH, Weihl CC. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol 187(6):875-88, 2009. e-Pub 2009. PMID: 20008565.
Cao X, Leonard K, Collins LI, Cai SF, Mayer JC, Payton JE, Walter MJ, Piwnica-Worms D, Schreiber RD, Ley TJ. Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res 69(22):8700-9, 2009. e-Pub 2009. PMID: 19843867.
Jost SC, Collins L, Travers S, Piwnica-Worms D, Garbow JR. Measuring brain tumor growth: combined bioluminescence imaging-magnetic resonance imaging strategy. Mol Imaging 8(5):245-53, 2009. e-Pub 2009. PMID: 19796602.
Barnett EM, Zhang X, Maxwell D, Chang Q, Piwnica-Worms D. Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model. Proc Natl Acad Sci U S A 106(23):9391-6, 2009. e-Pub 2009. PMID: 19458250.
Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113(24):6206-14, 2009. e-Pub 2009. PMID: 19050309.
Ju JS, Miller SE, Jackson E, Cadwell K, Piwnica-Worms D, Weihl CC. Quantitation of selective autophagic protein aggregate degradation in vitro and in vivo using luciferase reporters. Autophagy 5(4):511-9, 2009. e-Pub 2009. PMID: 19305149.
McDunn JE, Muenzer JT, Dunne B, Zhou A, Yuan K, Hoekzema A, Hilliard C, Chang KC, Davis CG, McDonough J, Hunt C, Grigsby P, Piwnica-Worms D, Hotchkiss RS. An anti-apoptotic peptide improves survival in lethal total body irradiation. Biochem Biophys Res Commun 382(4):657-62, 2009. e-Pub 2009. PMID: 19303399.
Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 44(5):908-16, 2009. e-Pub 2009. PMID: 19442620.
Carreno BM, Garbow JR, Kolar GR, Jackson EN, Engelbach JA, Becker-Hapak M, Carayannopoulos LN, Piwnica-Worms D, Linette GP. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases. Clin Cancer Res 15(10):3277-86, 2009. e-Pub 2009. PMID: 19447870.
Capoccia BJ, Robson DL, Levac KD, Maxwell DJ, Hohm SA, Neelamkavil MJ, Bell GI, Xenocostas A, Link DC, Piwnica-Worms D, Nolta JA, Hess DA. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood 113(21):5340-51, 2009. e-Pub 2009. PMID: 19324906.
Uluçkan O, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, Frazier WA, Weilbaecher KN. CD47 regulates bone mass and tumor metastasis to bone. Cancer Res 69(7):3196-204, 2009. e-Pub 2009. PMID: 19276363.
Gross S, Gammon ST, Moss BL, Rauch D, Harding J, Heinecke JW, Ratner L, Piwnica-Worms D. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med 15(4):455-61, 2009. e-Pub 2009. PMID: 19305414.
Maxwell D, Chang Q, Zhang X, Barnett EM, Piwnica-Worms D. An improved cell-penetrating, caspase-activatable, near-infrared fluorescent peptide for apoptosis imaging. Bioconjug Chem 20(4):702-9. (Most-accessed article), 2009. e-Pub 2009. PMID: 19331388.
Gammon ST, Villalobos VM, Roshal M, Samrakandi M, Piwnica-Worms D. Rational design of novel red-shifted BRET pairs: Platforms for real-time single-chain protease biosensors. Biotechnol Prog 25(2):559-69, 2009. e-Pub 2009. PMID: 19330851.
Yang KS, Ilagan MX, Piwnica-Worms D, Pike LJ. Luciferase fragment complementation imaging of conformational changes in the epidermal growth factor receptor. J Biol Chem 284(12):7474-82, 2009. e-Pub 2009. PMID: 19171934.
Parry JJ, Sharma V, Andrews R, Moros EG, Piwnica-Worms D, Rogers BE. PET imaging of heat-inducible suicide gene expression in mice bearing head and neck squamous cell carcinoma xenografts. Cancer Gene Ther 16(2):161-70, 2009. e-Pub 2009. PMID: 18758434.
Rauch D, Gross S, Harding J, Niewiesk S, Lairmore M, Piwnica-Worms D, Ratner L. Imaging spontaneous tumorigenesis: inflammation precedes development of peripheral NK tumors. Blood 113(7):1493-500, 2009. e-Pub 2009. PMID: 18971418.
Kesarwala AH, Samrakandi MM, Piwnica-Worms D. Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation. Cancer Res 69(3):976-83, 2009. e-Pub 2009. PMID: 19176375.
Pazolli E, Luo X, Brehm S, Carbery K, Chung JJ, Prior JL, Doherty J, Demehri S, Salavaggione L, Piwnica-Worms D, Stewart SA. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res 69(3):1230-9, 2009. e-Pub 2009. PMID: 19155301.
Rauch D, Gross S, Harding J, Bokhari S, Niewiesk S, Lairmore M, Piwnica-Worms D, Ratner L. T-cell activation promotes tumorigenesis in inflammation-associated cancer. Retrovirology 6:116, 2009. e-Pub 2009. PMID: 20017942.
Gross S, Gammon ST, Moss BL, Piwnica-Worms D. Real-time bioluminescence imaging of myeloperoxidase activity in small laboratory animals. Nature Protocols:DOI: 10.1038/nprot.2009.73, 2009. e-Pub 2009.
Goldhoff P, Warrington NM, Limbrick DD, Hope A, Woerner BM, Jackson E, Perry A, Piwnica-Worms D, Rubin JB. Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res 14(23):7717-25, 2008. e-Pub 2008. PMID: 19047098.
Pichler A, Prior JL, Luker GD, Piwnica-Worms D. Generation of a highly inducible Gal4-->Fluc universal reporter mouse for in vivo bioluminescence imaging. Proc Natl Acad Sci U S A 105(41):15932-7, 2008. e-Pub 2008. PMID: 18843112.
Flentie KN, Qi M, Gammon ST, Razia Y, Lui F, Marpegan L, Manglik A, Piwnica-Worms D, McKinney JS. Stably integrated luxCDABE for assessment of Salmonella invasion kinetics. Mol Imaging 7(5):222-33, 2008. e-Pub 2008. PMID: 19123992.
Uluçkan O, Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, Kramer M, Dowland N, Prior JL, Piwnica-Worms D, Jeong SS, Chen R, Weilbaecher K. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell Biochem 104(4):1311-23, 2008. e-Pub 2008. PMID: 18260128.
Moss BL, Gross S, Gammon ST, Vinjamoori A, Piwnica-Worms D. Identification of a ligand-induced transient refractory period in nuclear factor-kappaB signaling. J Biol Chem 283(13):8687-98, 2008. e-Pub 2008. PMID: 18203717.
Leevy WM, Gammon ST, Johnson JR, Lampkins AJ, Jiang H, Marquez M, Piwnica-Worms D, Suckow MA, Smith BD. Noninvasive optical imaging of staphylococcus aureus bacterial infection in living mice using a Bis-dipicolylamine-Zinc(II) affinity group conjugated to a near-infrared fluorophore. Bioconjug Chem 19(3):686-92, 2008. e-Pub 2008. PMID: 18260609.
Maxwell DJ, Bonde J, Hess DA, Hohm SA, Lahey R, Zhou P, Creer MH, Piwnica-Worms D, Nolta JA. Fluorophore-conjugated iron oxide nanoparticle labeling and analysis of engrafting human hematopoietic stem cells. Stem Cells 26(2):517-24, 2008. e-Pub 2008. PMID: 18055451.
McDunn JE, Muenzer JT, Rachdi L, Chang KC, Davis CG, Dunne WM, Piwnica-Worms D, Bernal-Mizrachi E, Hotchkiss RS. Peptide-mediated activation of Akt and extracellular regulated kinase signaling prevents lymphocyte apoptosis. FASEB J 22(2):561-8, 2008. e-Pub 2008. PMID: 17855622.
Zhao L, Kroenke CD, Song J, Piwnica-Worms D, Ackerman JJ, Neil JJ. Intracellular water-specific MR of microbead-adherent cells: the HeLa cell intracellular water exchange lifetime. NMR Biomed 21(2):159-64, 2008. e-Pub 2008. PMID: 17461436.
Zhao L, Sukstanskii AL, Kroenke CD, Song J, Piwnica-Worms D, Ackerman JJ, Neil JJ. Intracellular water specific MR of microbead-adherent cells: HeLa cell intracellular water diffusion. Magn Reson Med 59(1):79-84, 2008. e-Pub 2008. PMID: 18050315.
Villalobos V, Naik S, Piwnica-Worms D. Detection of protein-protein interactions in live cells and animals with split firefly luciferase protein fragment complementation. Methods Mol Biol 439:339-52, 2008. e-Pub 2008. PMID: 18370114.
Nervi B, Rettig MP, Ritchey JK, Wang HL, Bauer G, Walker J, Bonyhadi ML, Berenson RJ, Prior JL, Piwnica-Worms D, Nolta JA, DiPersio JF. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Exp Hematol 35(12):1823-38, 2007. e-Pub 2007. PMID: 17764813.
Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27(4):635-46, 2007. e-Pub 2007. PMID: 17919943.
Naik S, Piwnica-Worms D. Real-time imaging of beta-catenin dynamics in cells and living mice. Proc Natl Acad Sci U S A 104(44):17465-70, 2007. e-Pub 2007. PMID: 17954915.
Gross S, Moss BL, Piwnica-Worms D. Veni, vidi, vici: in vivo molecular imaging of immune response. Immunity 27(4):533-8, 2007. e-Pub 2007. PMID: 17967405.
Gammon ST, Bernstein M, Schuster DP, Piwnica-Worms D. A method for quantification of nucleotides and nucleotide analogues in thymidine kinase assays using lanthanum phosphate coprecipitation. Anal Biochem 369(1):80-6, 2007. e-Pub 2007. PMID: 17658449.
Hirbe AC, Rubin J, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci U S A 104(35):14062-7, 2007. e-Pub 2007. PMID: 17715292.
Kashiwagi H, McDunn JE, Goedegebuure PS, Gaffney MC, Chang K, Trinkaus K, Piwnica-Worms D, Hotchkiss RS, Hawkins WG. TAT-Bim induces extensive apoptosis in cancer cells. Ann Surg Oncol 14(5):1763-71, 2007. e-Pub 2007. PMID: 17206479.
Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, Piwnica-Worms D, Rich KM. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26(18):2563-73, 2007. e-Pub 2007. PMID: 17099729.
Bullok KE, Maxwell D, Kesarwala AH, Gammon S, Prior JL, Snow M, Stanley S, Piwnica-Worms D. Biochemical and in vivo characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. Biochemistry 46(13):4055-65, 2007. e-Pub 2007. PMID: 17348687.
Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood 109(8):3424-31, 2007. e-Pub 2007. PMID: 17192391.
Hurov JB, Huang M, White LS, Lennerz J, Choi CS, Cho YR, Kim HJ, Prior JL, Piwnica-Worms D, Cantley LC, Kim JK, Shulman GI, Piwnica-Worms H. Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo. Proc Natl Acad Sci U S A 104(13):5680-5, 2007. e-Pub 2007. PMID: 17372192.
Gross S, Abraham U, Prior JL, Herzog ED, Piwnica-Worms D. Continuous delivery of D-luciferin by implanted micro-osmotic pumps enables true real-time bioluminescence imaging of luciferase activity in vivo. Mol Imaging 6(2):121-30. (Cover), 2007. e-Pub 2007. PMID: 17445506.
Yang L, Jackson E, Woerner BM, Perry A, Piwnica-Worms D, Rubin JB. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res 67(2):651-8, 2007. e-Pub 2007. PMID: 17234775.
Saxena MT, Aton SJ, Hildebolt C, Prior JL, Abraham U, Piwnica-Worms D, Herzog ED. Bioluminescence imaging of period1 gene expression in utero. Mol Imaging 6(1):68-72, 2007. e-Pub 2007. PMID: 17311766.
Johnson JR, Fu N, Arunkumar E, Leevy WM, Gammon ST, Piwnica-Worms D, Smith BD. Squaraine rotaxanes: superior substitutes for Cy-5 in molecular probes for near-infrared fluorescence cell imaging. Angew Chem Int Ed Engl 46(29):5528-31, 2007. e-Pub 2007. PMID: 17585399.
Leevy WM, Gammon ST, Jiang H, Johnson JR, Maxwell DJ, Jackson EN, Marquez M, Piwnica-Worms D, Smith BD. Optical imaging of bacterial infection in living mice using a fluorescent near-infrared molecular probe. J Am Chem Soc 128(51):16476-7, 2006. e-Pub 2006. PMID: 17177377.
Kesarwala AH, Prior JL, Sun J, Harpstrite SE, Sharma V, Piwnica-Worms D. Second-generation triple reporter for bioluminescence, micro-positron emission tomography, and fluorescence imaging. Mol Imaging 5(4):465-74, 2006. e-Pub 2006. PMID: 17150159.
Ippolito JE, Merritt ME, Bäckhed F, Moulder KL, Mennerick S, Manchester JK, Gammon ST, Piwnica-Worms D, Gordon JI. Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers. Proc Natl Acad Sci U S A 103(33):12505-10, 2006. e-Pub 2006. PMID: 16895983.
Barnett EM, Elangovan B, Bullok KE, Piwnica-Worms D. Selective cell uptake of modified Tat peptide-fluorophore conjugates in rat retina in ex vivo and in vivo models. Invest Ophthalmol Vis Sci 47(6):2589-95, 2006. e-Pub 2006. PMID: 16723475.
Hotchkiss RS, McConnell KW, Bullok K, Davis CG, Chang KC, Schwulst SJ, Dunne JC, Dietz GP, Bähr M, McDunn JE, Karl IE, Wagner TH, Cobb JP, Coopersmith CM, Piwnica-Worms D. TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol 176(9):5471-7, 2006. e-Pub 2006. PMID: 16622015.
Gammon ST, Leevy WM, Gross S, Gokel GW, Piwnica-Worms D. Spectral unmixing of multicolored bioluminescence emitted from heterogeneous biological sources. Anal Chem 78(5):1520-7, 2006. e-Pub 2006. PMID: 16503603.
Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115(11):3285-90, 2005. e-Pub 2005. PMID: 16239972.
Leevy WM, Gammon ST, Levchenko T, Daranciang DD, Murillo O, Torchilin V, Piwnica-Worms D, Huettner JE, Gokel GW. Structure-activity relationships, kinetics, selectivity, and mechanistic studies of synthetic hydraphile channels in bacterial and mammalian cells. Org Biomol Chem 3(19):3544-50, 2005. e-Pub 2005. PMID: 16172693.
Abraham U, Prior JL, Granados-Fuentes D, Piwnica-Worms DR, Herzog ED. Independent circadian oscillations of Period1 in specific brain areas in vivo and in vitro. J Neurosci 25(38):8620-6, 2005. e-Pub 2005. PMID: 16177029.
Bullok K, Piwnica-Worms D. Synthesis and characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. J Med Chem 48(17):5404-7, 2005. e-Pub 2005. PMID: 16107137.
Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods 2(8):607-14, 2005. e-Pub 2005. PMID: 16094386.
Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 11(12):4487-94. (Cover), 2005. e-Pub 2005. PMID: 15958634.
Gillies RJ, Hoffman JM, Lam KS, Menkens AE, Piwnica-Worms DR, Sullivan DC, Weissleder R. Meeting report: high-throughput technologies for in vivo imaging agents. Mol Imaging 4(2):98-103, 2005. e-Pub 2005. PMID: 16105507.
Sharma V, Prior JL, Belinsky MG, Kruh GD, Piwnica-Worms D. Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med 46(2):354-64, 2005. e-Pub 2005. PMID: 15695797.
Bigott HM, Prior JL, Piwnica-Worms DR, Welch MJ. Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi. Mol Imaging 4(1):30-9, 2005. e-Pub 2005. PMID: 15967124.
Sharma V, Piwnica-Worms D. Monitoring multidrug resistance P-glycoprotein drug transport activity with SPECT and PET radiopharmaceuticals. Topics Curr Chem 252:155-78, 2005. e-Pub 2005.
Gross S, Piwnica-Worms D. Monitoring proteasome activity in cellulo and in living animals by bioluminescent imaging: technical considerations for design and use of genetically encoded reporters. Methods Enzymol 399:512-30, 2005. e-Pub 2005. PMID: 16338379.
Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64(23):8604-12, 2004. e-Pub 2004. PMID: 15574767.
Rettig MP, Ritchey JK, Prior JL, Haug JS, Piwnica-Worms D, DiPersio JF. Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation. J Immunol 173(6):3620-30, 2004. e-Pub 2004. PMID: 15356106.
Luker KE, Smith MC, Luker GD, Gammon ST, Piwnica-Worms H, Piwnica-Worms D. Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc Natl Acad Sci U S A 101(33):12288-93, 2004. e-Pub 2004. PMID: 15284440.
Richard JC, Zhou Z, Chen DL, Mintun MA, Piwnica-Worms D, Factor P, Ponde DE, Schuster DP. Quantitation of pulmonary transgene expression with PET imaging. J Nucl Med 45(4):644-54, 2004. e-Pub 2004. PMID: 15073262.
Pichler A, Prior JL, Piwnica-Worms D. Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl Acad Sci U S A 101(6):1702-7, 2004. e-Pub 2004. PMID: 14755051.
Zhao H, Doyle TC, Wong RJ, Cao Y, Stevenson DK, Piwnica-Worms D, Contag CH. Characterization of coelenterazine analogs for measurements of Renilla luciferase activity in live cells and living animals. Mol Imaging 3(1):43-54, 2004. e-Pub 2004. PMID: 15142411.
Prantner AM, Sharma V, Garbow JR, Piwnica-Worms D. Synthesis and characterization of a Gd-DOTA-D-permeation peptide for magnetic resonance relaxation enhancement of intracellular targets. Mol Imaging 2(4):333-41, 2003. e-Pub 2003. PMID: 14717332.
Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat Med 9(7):969-73, 2003. e-Pub 2003. PMID: 12819780.
Richard JC, Zhou Z, Ponde DE, Dence CS, Factor P, Reynolds PN, Luker GD, Sharma V, Ferkol T, Piwnica-Worms D, Schuster DP. Imaging pulmonary gene expression with positron emission tomography. Am J Respir Crit Care Med 167(9):1257-63, 2003. e-Pub 2003. PMID: 12505860.
Luker GD, Sharma V, Pica CM, Prior JL, Li W, Piwnica-Worms D. Molecular imaging of protein-protein interactions: controlled expression of p53 and large T-antigen fusion proteins in vivo. Cancer Res 63(8):1780-8, 2003. e-Pub 2003. PMID: 12702563.
Gammon ST, Villalobos VM, Prior JL, Sharma V, Piwnica-Worms D. Quantitative analysis of permeation peptide complexes labeled with Technetium-99m: chiral and sequence-specific effects on net cell uptake. Bioconjug Chem 14(2):368-76, 2003. e-Pub 2003. PMID: 12643747.
Ocheskey JA, Polyakov VR, Harpstrite SE, Oksman A, Goldberg DE, Piwnica-Worms D, Sharma V. Synthesis, characterization, and molecular structure of a gallium(III) complex of an amine-phenol ligand with activity against chloroquine-sensitive Plasmodium falciparum strains. J Inorg Biochem 93(3-4):265-70, 2003. e-Pub 2003. PMID: 12576290.
Luker GD, Bardill JP, Prior JL, Pica CM, Piwnica-Worms D, Leib DA. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J Virol 76(23):12149-61, 2002. e-Pub 2002. PMID: 12414955.
Bullok KE, Dyszlewski M, Prior JL, Pica CM, Sharma V, Piwnica-Worms D. Characterization of novel histidine-tagged Tat-peptide complexes dual-labeled with (99m)Tc-tricarbonyl and fluorescein for scintigraphy and fluorescence microscopy. Bioconjug Chem 13(6):1226-37, 2002. e-Pub 2002. PMID: 12440857.
Violini S, Sharma V, Prior JL, Dyszlewski M, Piwnica-Worms D. Evidence for a plasma membrane-mediated permeability barrier to Tat basic domain in well-differentiated epithelial cells: lack of correlation with heparan sulfate. Biochemistry 41(42):12652-61, 2002. e-Pub 2002. PMID: 12379107.
Luker GD, Sharma V, Pica CM, Dahlheimer JL, Li W, Ochesky J, Ryan CE, Piwnica-Worms H, Piwnica-Worms D. Noninvasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci U S A 99(10):6961-6, 2002. e-Pub 2002. PMID: 11997447.
Luker GD, Luker KE, Sharma V, Pica CM, Dahlheimer JL, Ocheskey JA, Fahrner TJ, Milbrandt J, Piwnica-Worms D. In vitro and in vivo characterization of a dual-function green fluorescent protein--HSV1-thymidine kinase reporter gene driven by the human elongation factor 1 alpha promoter. Mol Imaging 1(2):65-73, 2002. e-Pub 2002. PMID: 12920846.
Dyszlewski M, Blake HM, Dahlheimer JL, Pica CM, Piwnica-Worms D. Characterization of a novel 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity. Mol Imaging 1(1):24-35, 2002. e-Pub 2002. PMID: 12920858.
Luker GD, Flagg TP, Sha Q, Luker KE, Pica CM, Nichols CG, Piwnica-Worms D. MDR1 P-glycoprotein reduces influx of substrates without affecting membrane potential. J Biol Chem 276(52):49053-60, 2001. e-Pub 2001. PMID: 11598111.
Luker KE, Pica CM, Schreiber RD, Piwnica-Worms D. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res 61(17):6540-7, 2001. e-Pub 2001. PMID: 11522652.
Luker GD, Dahlheimer JL, Ostlund RE, Piwnica-Worms D. Decreased hepatic accumulation and enhanced esterification of cholesterol in mice deficient in mdr1a and mdr1b P-glycoproteins. J Lipid Res 42(9):1389-94, 2001. e-Pub 2001. PMID: 11518757.
Polyakov V, Sharma V, Dahlheimer JL, Pica CM, Luker GD, Piwnica-Worms D. Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy. Bioconjug Chem 11(6):762-71, 2000. e-Pub 2000. PMID: 11087323.
Chen WS, Luker KE, Dahlheimer JL, Pica CM, Luker GD, Piwnica-Worms D. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Biochem Pharmacol 60(3):413-26, 2000. e-Pub 2000. PMID: 10856437.
Luker GD, Pica CM, Kumar AS, Covey DF, Piwnica-Worms D. Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains. Biochemistry 39(26):7651-61, 2000. e-Pub 2000. PMID: 10869171.
Luker GD, Pica CM, Kumar AS, Covey DF, Piwnica-Worms D. Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains. Biochemistry 39(29):8692, 2000. e-Pub 2000. PMID: 10913278.
Sharma V, Beatty A, Wey SP, Dahlheimer J, Pica CM, Crankshaw CL, Bass L, Green MA, Welch MJ, Piwnica-Worms D. Novel gallium(III) complexes transported by MDR1 P-glycoprotein: potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo. Chem Biol 7(5):335-43. (Cover), 2000. e-Pub 2000. PMID: 10801474.
Sharma V, Piwnica-Worms D. Metal complexes for therapy and diagnosis of drug resistance. Chem Rev 99(9):2545-60, 1999. e-Pub 1999. PMID: 11749491.
Luker GD, Nilsson KR, Covey DF, Piwnica-Worms D. Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol. J Biol Chem 274(11):6979-91, 1999. e-Pub 1999. PMID: 10066752.
Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96(7):3900-5, 1999. e-Pub 1999. PMID: 10097135.
Polyakov VR, Sharma V, Crankshaw CL, Piwnica-Worms D. Synthesis, Molecular Structure, and Properties of a Neutral Schiff Base Phenolic Complex of Magnesium. Inorg Chem 37(18):4740-4742, 1998. e-Pub 1998. PMID: 11670631.
Rao VV, Herman LW, Kronauge JF, Piwnica-Worms D. A novel areneisonitrile Tc complex inhibits the transport activity of MDR P-glycoprotein. Nucl Med Biol 25(3):225-32, 1998. e-Pub 1998. PMID: 9620627.
Crankshaw CL, Marmion M, Luker GD, Rao V, Dahlheimer J, Burleigh BD, Webb E, Deutsch KF, Piwnica-Worms D. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein. J Nucl Med 39(1):77-86, 1998. e-Pub 1998. PMID: 9443741.
Luker GD, Rao VV, Crankshaw CL, Dahlheimer J, Piwnica-Worms D. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. Biochemistry 36(46):14218-27, 1997. e-Pub 1997. PMID: 9369495.
Bosch I, Crankshaw CL, Piwnica-Worms D, Croop JM. Characterization of functional assays of multidrug resistance P-glycoprotein transport activity. Leukemia 11(7):1131-7, 1997. e-Pub 1997. PMID: 9205002.
Goldberg DE, Sharma V, Oksman A, Gluzman IY, Wellems TE, Piwnica-Worms D. Probing the chloroquine resistance locus of Plasmodium falciparum with a novel class of multidentate metal(III) coordination complexes. J Biol Chem 272(10):6567-72, 1997. e-Pub 1997. PMID: 9045684.
Luker GD, Fracasso PM, Dobkin J, Piwnica-Worms D. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J Nucl Med 38(3):369-72. (Cover), 1997. e-Pub 1997. PMID: 9074520.
Sharma V, Beatty A, Goldberg DE, Piwnica-Worms D. Structure of a novel gallium(III) complex with selective activity against chloroquine-resistant P. falciparum. J Chem Soc Chem Commun:2223-4, 1997. e-Pub 1997.
Reimold SC, Maier SE, Aggarwal K, Fleischmann KE, Piwnica-Worms D, Kikinis R, Lee RT. Aortic flow velocity patterns in chronic aortic regurgitation: implications for Doppler echocardiography. J Am Soc Echocardiogr 9(5):675-83, 1996. e-Pub 1996. PMID: 8887871.
Sharma V, Crankshaw CL, Piwnica-Worms D. Effects of multidrug resistance (MDR1) P-glycoprotein expression levels and coordination metal on the cytotoxic potency of multidentate (N4O2) (ethylenediamine)bis[propyl(R-benzylimino)]metal(III) cations. J Med Chem 39(18):3483-90, 1996. e-Pub 1996. PMID: 8784446.
Piwnica-Worms D. Oncological applications of Tc-99m-SESTAMIBI, Tc-99m-Q-complexes and other Tc-99m based lipophilic cations.(Published in French). Revue de L’ACOMEN 2:92-100, 1996. e-Pub 1996.
Rao VV, Anthony DC, Piwnica-Worms D. Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase. J Histochem Cytochem 43(12):1187-92, 1995. e-Pub 1995. PMID: 8537634.
Piwnica-Worms D, Rao VV, Kronauge JF, Croop JM. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 34(38):12210-20, 1995. e-Pub 1995. PMID: 7547962.
Schwartz LH, Seltzer SE, Tempany CM, Silverman SG, Piwnica-Worms DR, Adams DF, Herman L, Herman LA, Hooshmand R. Superparamagnetic iron oxide hepatic MR imaging: efficacy and safety using conventional and fast spin-echo pulse sequences. J Magn Reson Imaging 5(5):566-70, 1995. e-Pub 1995. PMID: 8574043.
Baum S, Eckelman WC, Garcia EV, Holman BL, Kung HF, Mattrey RF, Piwnica-Worms D, Wahl RL, Watson JT. Contrast media and radiopharmaceutical agents: regulatory issues. Acad Radiol 2 Suppl 2:S92-3, 1995. e-Pub 1995. PMID: 9419707.
Piwnica-Worms D. In vivo biochemistry, pharmacology, and physiology. Acad Radiol 2 Suppl 2:S98-9, 1995. e-Pub 1995. PMID: 9419710.
Katzenellenbogen JA, Coleman RE, Hawkins RA, Krohn KA, Larson SM, Mendelsohn J, Osborne CK, Piwnica-Worms D, Reba RC, Siegel BA. Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. Clin Cancer Res 1(8):921-32, 1995. e-Pub 1995. PMID: 9816063.
Herman LW, Sharma V, Kronauge JF, Barbarics E, Herman LA, Piwnica-Worms D. Novel hexakis(areneisonitrile)technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein. J Med Chem 38(15):2955-63, 1995. e-Pub 1995. PMID: 7636856.
Piwnica-Worms D. Challenges of imaging gene translation with radiolabeled oligonucleotides. Q J Nucl Med 39:13-14, 1995. e-Pub 1995. PMID: 8195871.
Piwnica-Worms D. Making sense out of anti-sense: challenges of imaging gene translation with radiolabeled oligonucleotides. J Nucl Med 35(6):1064-6, 1994. e-Pub 1994. PMID: 8195871.
Schwartz LH, Seltzer SE, Adams DF, Tempany CM, Piwnica-Worms DR, Silverman SG, Herman L, Herman LT, Hooshmand R. Effects of superparamagnetic iron oxide (AMI-25) on liver and spleen imaging using spin-echo and fast spin-echo magnetic resonance pulse sequences. Invest Radiol 29 Suppl 2:S21-3, 1994. e-Pub 1994. PMID: 7928234.
Reimold SC, Maier SE, Fleischmann KE, Khatri M, Piwnica-Worms D, Kikinis R, Lee RT. Dynamic nature of the aortic regurgitant orifice area during diastole in patients with chronic aortic regurgitation. Circulation 89(5):2085-92, 1994. e-Pub 1994. PMID: 8181132.
Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 35(3):510-5. (Award of Merit), 1994. e-Pub 1994. PMID: 7906729.
Rao VV, Anthony DC, Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 54(6):1536-41, 1994. e-Pub 1994. PMID: 7511043.
Piwnica-Worms DP, Kronauge JF, LeFurgey A, Backus M, Hockett D, Ingram P, Lieberman M, Holman BL, Jones AG, Davison A. Mitochondrial localization and characterization of 99Tc-SESTAMIBI in heart cells by electron probe X-ray microanalysis and 99Tc-NMR spectroscopy. Magn Reson Imaging 12(4):641-52, 1994. e-Pub 1994. PMID: 8057769.
Schwartz LH, Seltzer SE, Tempany CM, Silverman SG, Piwnica-Worms DR, Adams DF, Herman L, Herman LT, Hooshmand R. Prospective comparison of T2-weighted fast spin-echo, with and without fat suppression, and conventional spin-echo pulse sequences in the upper abdomen. Radiology 189(2):411-6, 1993. e-Pub 1993. PMID: 8210368.
Backus M, Piwnica-Worms D, Hockett D, Kronauge J, Lieberman M, Ingram P, LeFurgey A. Microprobe analysis of Tc-MIBI in heart cells: calculation of mitochondrial membrane potential. Am J Physiol 265(1 Pt 1):C178-87, 1993. e-Pub 1993. PMID: 8338127.
Chernoff DM, Strichartz GR, Piwnica-Worms D. Membrane potential determination in large unilamellar vesicles with hexakis(2-methoxyisobutylisonitrile)technetium(I). Biochim Biophys Acta 1147(2):262-6, 1993. e-Pub 1993. PMID: 8476920.
Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53(5):977-84, 1993. e-Pub 1993. PMID: 8094997.
Piwnica-Worms D, Chiu ML, Kronauge JF. Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI. Cancer Chemother Pharmacol 32(5):385-91, 1993. e-Pub 1993. PMID: 8339390.
Chiu ML, Herman LW, Kronauge JF, Piwnica-Worms D. Comparative effects of neutral dipolar compounds and lipophilic anions on technetium 99m-hexakis (2-methoxyisobutyl isonitrile) accumulation in cultured chick ventricular myocytes. Invest Radiol 27(12):1052-8, 1992. e-Pub 1992. PMID: 1473924.
Patz EF, Shaffer K, Piwnica-Worms DR, Jochelson M, Sarin M, Sugarbaker DJ, Pugatch RD. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol 159(5):961-6, 1992. e-Pub 1992. PMID: 1414807.
Carvalho PA, Chiu ML, Kronauge JF, Kawamura M, Jones AG, Holman BL, Piwnica-Worms D. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 33(8):1516-22, 1992. e-Pub 1992. PMID: 1634944.
Piwnica-Worms D, Chiu ML, Kronauge JF. Divergent kinetics of 201Tl and 99mTc-SESTAMIBI in cultured chick ventricular myocytes during ATP depletion. Circulation 85(4):1531-41, 1992. e-Pub 1992. PMID: 1313342.
Kandarpa K, Piwnica-Worms D, Chopra PS, Admas DF, Hunink MG, Donaldson MC, Whittemore AD, Mannick JA, Harrington DP. Prospective double-blinded comparison of MR imaging and aortography in the preoperative evaluation of abdominal aortic aneurysms. J Vasc Interv Radiol 3(1):83-9, 1992. e-Pub 1992. PMID: 1540717.
Kronauge JF, Chiu ML, Cone JS, Davison A, Holman BL, Jones AG, Piwnica-Worms D. Comparison of neutral and cationic myocardial perfusion agents: characteristics of accumulation in cultured cells. Int J Rad Appl Instrum B 19(2):141-8, 1992. e-Pub 1992. PMID: 1601667.
Piwnica-Worms D, Kronauge JF, Chiu ML. Enhancement by tetraphenylborate of technetium-99m-MIBI uptake kinetics and accumulation in cultured chick myocardial cells. J Nucl Med 32(10):1992-9. (Award of Merit), 1991. e-Pub 1991. PMID: 1919744.
Klein MA, Winalski CS, Wax MR, Piwnica-Worms DR. MR imaging of septic sacroiliitis. J Comput Assist Tomogr 15(1):126-32, 1991. e-Pub 1991. PMID: 1987181.
Liu S, Piwnica-Worms D, Lieberman M. Intracellular pH regulation in cultured embryonic chick heart cells. Na(+)-dependent Cl-/HCO3- exchange. J Gen Physiol 96(6):1247-69, 1990. e-Pub 1990. PMID: 1962815.
Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 82(5):1826-38, 1990. e-Pub 1990. PMID: 2225379.
Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 31(10):1646-53, 1990. e-Pub 1990. PMID: 2213187.
Piwnica-Worms D, Holman BL. Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes. J Nucl Med 31(7):1166-7, 1990. e-Pub 1990. PMID: 2362196.
Piwnica-Worms D, Kronauge JF, Delmon L, Holman BL, Marsh JD, Jones AG. Effect of metabolic inhibition on technetium-99m-MIBI kinetics in cultured chick myocardial cells. J Nucl Med 31(4):464-72, 1990. e-Pub 1990. PMID: 2324822.
Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 50(7):2198-202, 1990. e-Pub 1990. PMID: 2317808.
Liu S, Jacob R, Piwnica-Worms D, Lieberman M. Interaction of (Na + K + 2 Cl) cotransport and the Na/K pump in cultured chick cardiac myocytes. Mol Cell Biochem 89(2):147-50, 1989. e-Pub 1989. PMID: 2811863.
Piwnica-Worms D, Kronauge JF, Holman BL, Davison A, Jones AG. Comparative myocardial uptake characteristics of hexakis (alkylisonitrile) technetium(I) complexes. Effect of lipophilicity. Invest Radiol 24(1):25-9 (Stauffer Award), 1989. e-Pub 1989. PMID: 2917819.
Piwnica-Worms D, Kronauge JF, Holman BL, Lister-James J, Davison A, Jones AG. Hexakis(carbomethoxyisopropylisonitrile) technetium(I), a new myocardial perfusion imaging agent: binding characteristics in cultured chick heart cells. J Nucl Med 29(1):55-61, 1988. e-Pub 1988. PMID: 3335928.
Liu S, Jacob R, Piwnica-Worms D, Lieberman M. (Na + K + 2Cl) cotransport in cultured embryonic chick heart cells. Am J Physiol 253(5 Pt 1):C721-30, 1987. e-Pub 1987. PMID: 3688219.
Jacob R, Lieberman M, Murphy E, Piwnica-Worms D. Effects of sodium-potassium pump inhibition and low sodium on membrane potential in cultured embryonic chick heart cells. J Physiol 387:549-66, 1987. e-Pub 1987. PMID: 2443685.
English RJ, Tumeh SS, Piwnica-Worms D, Holman BL. SPECT imaging in evaluating extent of malignant external otitis. J Nuc Med Tech 15:8-10, 1987. e-Pub 1987.
Piwnica-Worms D, Jacob R, Shigeto N, Horres CR, Lieberman M. Na/H exchange in cultured chick heart cells: secondary stimulation of electrogenic transport during recovery from intracellular acidosis. J Mol Cell Cardiol 18(11):1109-16, 1986. e-Pub 1986. PMID: 3025458.
Piwnica-Worms D, Forman A, Tumeh SS. Chronic ear discharge in an elderly diabetic man. Invest Radiol 21(7):584-8, 1986. e-Pub 1986. PMID: 3488299.
Jacob R, Piwnica-Worms D, Horres CR, Lieberman M. Electroneutral Na/H exchange may depolarize the membrane potential in steady state. J Gen Physiol 86(6):891-5, 1985. e-Pub 1985. PMID: 2416872.
Piwnica-Worms D, Jacob R, Horres CR, Lieberman M. Potassium-chloride cotransport in cultured chick heart cells. Am J Physiol 249(3 Pt 1):C337-44, 1985. e-Pub 1985. PMID: 4037074.
Piwnica-Worms D, Jacob R, Horres CR, Lieberman M. Na/H exchange in cultured chick heart cells. pHi regulation. J Gen Physiol 85(1):43-64, 1985. e-Pub 1985. PMID: 3968533.
Jacob R, Piwnica-Worms D, Horres CR, Lieberman M. Theoretical effects of transmembrane electroneutral exchange on membrane potential. J Gen Physiol 83(1):47-56, 1984. e-Pub 1984. PMID: 6319544.
Lieberman M, Horres CR, Jacob R, Murphy E, Piwnica-Worms D, Wheeler DM. Physiologic criteria for electrogenic transport in tissue-cultured heart cells. Soc Gen Physiol Ser 38:181-91, 1984. e-Pub 1984. PMID: 6695208.
Piwnica-Worms D, Jacob R, Horres CR, Lieberman M. Transmembrane chloride flux in tissue-cultured chick heart cells. J Gen Physiol 81(5):731-48, 1983. e-Pub 1983. PMID: 6864192.
Piwnica-Worms D, Lieberman M. Microfluorometric monitoring of pHi in cultured heart cells: Na+-H+ exchange. Am J Physiol 244(5):C422-8, 1983. e-Pub 1983. PMID: 6846529.

Invited Articles

Piwnica-Worms D. Illuminating cancer in vivo with molecular imaging: Introduction. Cancer J 21(3):150-151, 2015. e-Pub 2015. PMID: 26049693.
Anderson CJ, Piwnica-Worms D. SNM and AACR announce joint conference. J Nucl Med 53(3):18NA, 2012. e-Pub 2012. PMID: 22393231.
Dothager RS, Piwnica-Worms D. AACR Special Meeting Report: Nano in cancer - linking chemistry, biology, and clinical applications in vivo. Cancer Res(71):5611-15, 2011. e-Pub 2011.
Cheng KT, Piwnica-Worms D. Ac-rkkrrqrrrGK(QSY21)DEVDAPC(Alexa Fluor 647)-NH2. TCAPQ647. Molecular Imaging and Contrast Agent Database (MICAD) [database online]. National Library of Medicine (US), NCBI, 2008. e-Pub 2008.
Piwnica-Worms D. Spying on signal transduction and protein interactions. Molecular Imaging Gateway. Society of Nuclear Medicine MICoE:1-3, 2007. e-Pub 2007.
Piwnica-Worms D. Molecular imaging in the postgenomic era. Imaging Economics. CurAnt Communications 14:12-16, 2001. e-Pub 2001.

Review Articles

Gammon ST, Liu TW, Piwnica-Worms D. Interrogating Cellular Communication in Cancer with Genetically Encoded Imaging Reporters. Radiol Imaging Cancer 2(4):e190053, 2020. e-Pub 2020. PMID: 32803164.
Powell E, Piwnica-Worms D, Piwnica-Worms H. Contributions of p53 to metastasis. Cancer Discov 4(4):405-14, 2014. e-Pub 2014. PMID: 24658082.
Piwnica-Worms D. On in vivo imaging in cancer. Cold Spring Harb Perspect Biol 4(3), 2012. e-Pub 2012. PMID: 22383756.
Piwnica-Worms D, Sharma V. Probing multidrug resistance P-glycoprotein transporter activity with SPECT radiopharmaceuticals. Curr Top Med Chem 10(17):1834-45, 2010. e-Pub 2010. PMID: 20645914.
Dothager RS, Piwnica-Worms D. Molecular imaging of pulmonary disease in vivo. Proc Am Thorac Soc 6(5):403-10, 2009. e-Pub 2009. PMID: 19687211.
Dothager RS, Flentie K, Moss B, Pan MH, Kesarwala A, Piwnica-Worms D. Advances in bioluminescence imaging of live animal models. Curr Opin Biotechnol 20(1):45-53, 2009. e-Pub 2009. PMID: 19233638.
Villalobos V, Naik S, Piwnica-Worms D. Current state of imaging protein-protein interactions in vivo with genetically encoded reporters. Annu Rev Biomed Eng 9:321-49, 2007. e-Pub 2007. PMID: 17461729.
Piwnica-Worms D, Kesarwala AH, Pichler A, Prior JL, Sharma V. Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein--monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease. Neuroimaging Clin N Am 16(4):575-89, viii, 2006. e-Pub 2006. PMID: 17148020.
Gross S, Piwnica-Worms D. Molecular imaging strategies for drug discovery and development. Curr Opin Chem Biol 10(4):334-42, 2006. e-Pub 2006. PMID: 16822702.
Bullok KE, Gammon ST, Violini S, Prantner AM, Villalobos VM, Sharma V, Piwnica-Worms D. Permeation peptide conjugates for in vivo molecular imaging applications. Mol Imaging 5(1):1-15, 2006. e-Pub 2006. PMID: 16779965.
Gross S, Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7(1):5-15, 2005. e-Pub 2005. PMID: 15652745.
Piwnica-Worms D, Luker KE. Imaging protein-protein interactions in whole cells and living animals. Ernst Schering Res Found Workshop(49):35-41, 2005. e-Pub 2005. PMID: 15524209.
Piwnica-Worms D, Schuster DP, Garbow JR. Molecular imaging of host-pathogen interactions in intact small animals. Cell Microbiol 6(4):319-31, 2004. e-Pub 2004. PMID: 15009024.
Schuster DP, Kovacs A, Garbow J, Piwnica-Worms D. Recent advances in imaging the lungs of intact small animals. Am J Respir Cell Mol Biol 30(2):129-38, 2004. e-Pub 2004. PMID: 14729505.
Piwnica-Worms DR. Introduction to molecular imaging. J Am Coll Radiol 1(1 Suppl):2-3, 2004. e-Pub 2004. PMID: 17411748.
Cheng KT, Piwnica-Worms D. Ac-rkkrrorrrGK(QSY21)DEVDAPC(Alexa Fluor 647)-NH(2), 2004. e-Pub 2004. PMID: 20641692.
Luker KE, Piwnica-Worms D. Optimizing luciferase protein fragment complementation for bioluminescent imaging of protein-protein interactions in live cells and animals. Methods Enzymol 385:349-60, 2004. e-Pub 2004. PMID: 15130748.
Luker GD, Sharma V, Piwnica-Worms D. Visualizing protein-protein interactions in living animals. Methods 29(1):110-22, 2003. e-Pub 2003. PMID: 12543076.
Sharma V, Luker GD, Piwnica-Worms D. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging 16(4):336-51, 2002. e-Pub 2002. PMID: 12353250.
Slapak CA, Dahlheimer J, Piwnica-Worms D. Reversal of multidrug resistance with LY335979: functional analysis of P-glycoprotein-mediated transport activity and its modulation in vivo. J Clin Pharmacol Suppl:29S-38S, 2001. e-Pub 2001. PMID: 11452726.
Luker GD, Piwnica-Worms D. Molecular imaging in vivo with PET and SPECT. Acad Radiol 8(1):4-14, 2001. e-Pub 2001. PMID: 11201455.
Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 12(5):450-8, 2000. e-Pub 2000. PMID: 10975553.
Piwnica-Worms D, Marmion M. Characterization of drug specificity by pharmacokinetic analysis in gene knockout mice. J Clin Pharmacol Suppl:30S-33S, 1999. e-Pub 1999. PMID: 10434245.
Bae KT, Piwnica-Worms D. Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates. Q J Nucl Med 41(2):101-10, 1997. e-Pub 1997. PMID: 9203849.
Simons GR, Piwnica-Worms DR, Goldhaber SZ. Ovarian vein thrombosis. Am Heart J 126(3 Pt 1):641-7, 1993. e-Pub 1993. PMID: 8362720.

Professional Educational Materials

Piwnica-Worms D. Imaging Gene Expression and Protein Function In Vivo. In Fundamentals of Molecular Imaging Video Lecture Series. Commission on Molecular Imaging, American College of Radiology, 2006.

Editorials

Titus M, Frigo D, Efstathiou E, Logothetis CJ, Piwnica-Worms D, Bhattacharya PK. Metabolic imaging in prostate cancer. UroToday, 2018.
Colen RR, Piwnica-Worms D. Radiomics and radiogenomics in breast cancer. Breast Diseases: A Year Book Quarterly 27(1):23-24, 2016.

Abstracts

Muzzioli R, Pisaneschi P, Gammon, ST, Piwnica-Worms, D. [18F]Talazoparib: a novel potential PET imaging agent of PARP 96-97:S7-S8, 2021. e-Pub 2021.
Muzzioli R, Pisaneschi P, Gammon, ST, Piwnica-Worms, D. ENBPI ligand for 68 Ga: synthesis, radiolabeling optimization, and pilot myocardial perfusion imaging with ECG-gated PET 96-97:S57, 2021. e-Pub 2021.

Book Chapters

Gammon ST, Liu TW, Piwnica-Worms D. Eavesdropping on Intercellular Communication with Genetically Encoded Imaging Reporters. In: Visualizing Chemical Communications Among Migratory Cells In Vivo. Springer International Publishing, AG, 2020.
Piwnica-Worms D. On In Vivo Imaging in Cancer. In: Cold Spring Harbor Perspectives in Biology: The Mammary Gland as an Experimental Model. Cold Spring Harbor Laboratory Press, doi: 4:a013409, 2012.
Patlak M, S Nass Piwnica-Worms D. National Cancer Policy Forum Committee. In: Improving the Quality of Cancer Clinical Trials: Workshop Summary. Institute of Medicine, National Academies Press, 124, 2008.
Naik S, Moss BL, Pichler-Wallace A, Piwnica-Worms D. Imaging cellular networks and protein-protein interactions in vivo. In: Molecular Imaging in Oncology. Informa Healthcare USA, 391-403, 2008.
Villalobos V, Naik S, Piwnica-Worms D. Detection of protein-protein interactions in live cells and animals with split Firefly luciferase protein fragment complementation. In: Methods in Molecular Biology, Genomics Protocols. 2. Humana Press, 339-52, 2008.
Pichler A, Piwnica-Worms D. Overview of cardiovascular molecular imaging. In: Cardiovascular Molecular Imaging. Informa Healthcare USA, 1-9, 2007.
Piwnica-Worms D, Kesarwala AH, Pichler A, Prior JL, Sharma V. SPECT and PET imaging of multidrug resistant P-glycoprotein: monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer’s disease. In: Neuroimaging Clinics of North America: Molecular Neuroimaging. Elsevier, 575-89, 2006.
Piwnica-Worms D, Luker KE. Imaging protein-protein interactions in whole cells and living animals. In: Molecular Imaging - An Essential Tool in Preclinical Research, Diagnostic Imaging, and Therapy. Ernst Schering Research Foundation, Springer-Verlag, 35-41, 2005.
Piwnica-Worms D, Luker KE, Villalobos VM. Molecular imaging of protein-protein interactions in living animals. In: Molecular Imaging of the Lungs. Taylor & Francis Group, 313-26, 2005.
Piwnica-Worms D, Luker GD, Anderson C, Wahl RL. Molecular imaging in oncology. In: Molecular Nuclear Medicine: The Challenge of Genomics and Proteomics to Clinical Practice. Springer-Verlag, 633-51, 2003.
Luker GD, Sharma V, Piwnica-Worms D. Noninvasive imaging of protein-protein interactions in living animals. In: Handbook of Proteomic Methods. Humana Press, 283-98, 2003.
Piwnica-Worms D. Perspectives in imaging: present and future prospects of clinical molecular imaging. In: Holland-Frei Cancer Medicine. 6. B.C. Decker, 551-6, 2003.
Piwnica-Worms D, Luker KE, Fracasso PM. Multidrug resistance, Part A: Breast cancer. In: Nuclear Oncology. Lippincott Williams & Wilkins, 63-72, 2001.
Piwnica-Worms D. Functional identification of multidrug resistance gene expression in vivo. In: American Society of Clinical Oncology Spring 2000 Educational Book. ASCO Publications and Lippincott Williams & Wilkins, 178-84, 2000.
Piwnica-Worms D, Luker GD, Luker KE, Rao VV, Sharma V. Imaging gene expression in cancer: functional identification of multidrug resistance (MDR1) P-glycoprotein in vivo. In: Medical Radiology - Diagnostic Imaging and Radiation Oncology: Diagnostic Nuclear Medicine. Springer-Verlag, 273-83, 2000.
Luker GD, Luker KE, Sharma V, Rao VV, Piwnica-Worms D. Assessment of multidrug resistance. In: Nuclear Oncology. Springer-Verlag, 371-81, 1999.
Piwnica-Worms D, Kronauge JF. Transport mechanisms of SPECT perfusion tracers in cultured cells. In: Nuclear Cardiology: State of the Art and Future Directions. C.V. Mosby Co, 25-34, 1993.
Piwnica-Worms D, Jacob R, Lieberman, M. Properties of Na/H exchange in excitable tissues. In: Na/H Exchange. CRC press, 91-101, 1988.
Horres CR, Wheeler DM, Piwnica-Worms D, Lieberman M. Ion transport in cultured heart cells. In: The Heart Cell in Culture. CRC Press, 77-108, 1987.
Lieberman M, Horres CR, Jacob R, Murphy E, Piwnica-Worms D, Wheeler DM. Physiologic criteria for electrogenic transport in tissue-cultured heart cells. In: Electrogenic Transport: Fundamental Principles and Physiological Implications. Raven Press, 181-91, 1984.
Piwnica-Worms, D. Electroneutral Ion Gradient-Coupled Membrane Transport in Cultured Chick Heart Cells. In: Ph.D. Thesis. Duke University, 198, 1983.

Patents

Piwnica-Worms D. Membrane-Permeant Peptide Complexes for Medical Imaging, Diagnostics and Pharmaceutical Therapy. Patent Number: 7,306,783.
Piwnica-Worms D. Membrane-Permeant Peptide Complexes for Medical Imaging, Diagnostics and Pharmaceutical Therapy. Patent Number: 6,589,503.
Piwnica-Worms D. Membrane-Permeant Peptide Complexes for Medical Imaging, Diagnostics and Pharmaceutical Therapy. Patent Number: 7,306,784.
Piwnica-Worms D. Evaluation and Treatment of the Multidrug Resistance Phenotype. Patent Number: 5,403,574.
Piwnica-Worms D, Luker K, Luker G. Imaging Regulated Protein-Protein Interactions in Cells and Living Animals by Enhanced Luciferase Protein Fragment Complementation. Patent Number: 7,442,518.
Piwnica-Worms D. Enhancement of Cellular Accumulation of Lipophilic Cationic Organometallic Compounds by Reduction of Intramembrane Potential. Patent Number: 5,186,923.
Piwnica-Worms D. Membrane-Permeant Peptide Complexes for Medical Imaging, Diagnostics and Pharmaceutical Therapy. Patent Number: 6,348,185.
Piwnica-Worms D. Evaluation of the Multidrug Resistance Phenotype. Patent Number: 5,407,653.
Piwnica-Worms D, Gross S, Sharma V, Gammon S. Bioluminescence Imaging of Myeloperoxidase Activity In Vivo, Methods, Compositions, and Apparatuses. Patent Number: 8,652,442.
Sharma V, Sivapackiam J, Piwnica-Worms D. PET/SPECT Agents for Applications in Biomedical Imaging. Patent Number: 9,579,408.
Piwnica-Worms D. In Vivo Enhancement of Cellular Accumulation of Lipophilic Cationic Organometallic Compounds by Reduction of Intramembrane Potential. Patent Number: 5,277,897.
Hotchkiss R, Piwnica-Worms D, McDunn J. Membrane-permeant peptide complexes for treatment of sepsis. Patent Number: 8,038,984.
Sharma V, Piwnica-Worms D. Blood Brain Barrier Permeation Peptides. Patent Number: 7,803,351.

Less

CV information above last modified July 31, 2025

David R. Piwnica-Worms, M.D., Ph.D.

About Dr. David R. Piwnica-Worms

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Editorials

Abstracts

Book Chapters

Patents

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

David R. Piwnica-Worms, M.D., Ph.D.

About Dr. David R. Piwnica-Worms

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Editorials

Abstracts

Book Chapters

Patents

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer